Range Impact (RNGE) S-1/A 6 Dec 16 IPO registration (amended) Financial data

Document And Entity Information

Document And Entity Information	6 Months Ended
	Sep. 30, 2016
Document And Entity Information [Abstract]
Entity Registrant Name	Vitality Biopharma, Inc.
Entity Central Index Key	1,438,943
Document Type	S-1/A
Document Period End Date	Sep. 30, 2016
Amendment Description	Amendment No. 3
Amendment Flag	true
Current Fiscal Year End Date	--03-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	VBIO

Condensed Balance Sheets

Condensed Balance Sheets - USD ($)	Sep. 30, 2016	Mar. 31, 2016	Mar. 31, 2015
Current Assets
Cash	$ 33,664	$ 95,433	$ 389,730
Accounts receivable, net	27,936	30,396	61,595
Inventory	6,470	6,470	8,478
Prepaid Expense and other current assets			2,500
Deposit	3,058	2,500
Total Assets	71,128	134,799	462,303
Current Liabilities
Accounts payable and accrued liabilities	307,070	244,937	134,007
Accounts payable - related party	20,700	6,900	1,000
Derivative liability	663,810	401,127	1,406,596
Total liabilities	991,580	652,964	1,541,603
Stockholders' Deficit
Common stock, par value $0.001 per share; 1,000,000,000 shares authorized; 10,561,708, 7,911,708 and 7,296,892 shares issued and outstanding, respectively	12,945	7,912	7,297
Shares issuable, 588,236 and 999,700 shares, respectively		99,970
Additional paid-in-capital	13,169,086	11,890,512	11,288,637
Accumulated deficit	(14,102,483)	(12,516,559)	(12,375,234)
Total stockholders' deficit	(920,452)	(518,165)	(1,079,300)
Total liabilities and stockholders' deficit	$ 71,128	$ 134,799	$ 462,303

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2016	Mar. 31, 2016	Mar. 31, 2015	Oct. 11, 2011	Oct. 09, 2011
Balance Sheet Related Disclosures [Abstract]
Common stock, par value	$ 0.001	$ 0.001	$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized	1,000,000,000	1,000,000,000	1,000,000,000	525,000,000	75,000,000
Common stock, shares issued	14,380,968	7,911,708	7,296,892	51,450,000	7,350,000
Common stock, shares outstanding	14,380,968	7,911,708	7,296,892	51,450,000	7,350,000
Shares issuable	0	999,700	999,700

Condensed Statements of Operati

Condensed Statements of Operations - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Mar. 31, 2016	Mar. 31, 2015
Income Statement [Abstract]
Revenues	$ 45,888	$ 51,697	$ 92,265	$ 113,612	$ 248,348	$ 245,680
Cost of goods sold	20,893	41,199	46,012	65,232	149,478	121,341
Gross profit	24,995	10,498	46,253	48,380	98,870	124,339
Operating Expenses:
General and administrative	706,609	556,945	1,034,483	1,298,541	2,196,922	2,749,153
Rent and other related party costs	6,900	4,900	13,800	15,800	30,600	49,017
Research and development	129,902	143,133	240,217	326,658	613,119	1,131,327
Total Operating Expenses	843,411	704,978	1,288,500	1,640,999	2,840,641	3,929,497
Loss from operations	(818,416)	(694,480)	(1,242,247)	(1,592,619)	(2,741,771)	(3,805,158)
Other income (expenses)
Cost to induce exercise of warrants						(961,767)
Interest expense	(95)	(148)	(716)	(216)	(363)	(6,065)
Change in fair value of derivative liability	(328,008)	1,198,954	(342,961)	2,312,755	2,600,809	724,617
Total other income (expense), net	(328,103)	1,198,806	(343,677)	2,312,539	2,600,446	(243,215)
Net income (loss)	$ (1,146,519)	$ 504,326	$ (1,585,924)	$ 719,920	$ (141,325)	$ (4,048,373)
Net income (loss) per common share - Basic	$ (0.09)	$ 0.06	$ (0.15)	$ 0.09
Net income (loss) per common share - Diluted	$ (0.09)	$ 0.06	$ (0.15)	$ 0.09
Loss per share - Basic and diluted					$ (0.02)	$ (0.57)
Weighted average number of common shares outstanding, basic	12,247,463	7,857,120	10,916,841	7,722,334
Weighted average number of common shares outstanding, diluted	12,247,463	7,857,120	10,916,841	7,722,334
Weighted average number of common shares outstanding, basic and diluted					7,541,984	7,042,188

Condensed Statement of Stockhol

Condensed Statement of Stockholders' Deficit - USD ($)	Common Stock [Member]	Additional Paid In Capital [Member]	Accumulated Deficit [Member]	Common Stock Issuable [Member]	Unvested Issued Common Stock [Member]	Total
Balance at Mar. 31, 2014	$ 6,683	$ 8,359,516	$ (8,326,861)		$ (149,714)	$ (110,376)
Balance, shares at Mar. 31, 2014	6,683,252
Reclassication of unvested, issued common stock to paid-in capital		(149,714)			149,714
Common stock issued upon exercise of options	$ 5	4,995				$ 5,000
Common stock issued upon exercise of options, shares	5,000					5,000
Common stock issued to employees with vesting terms	$ 150	329,361				$ 329,511
Common stock issued to employees with vesting terms, shares	150,000
Common stock issued for services	$ 91	338,809				338,900
Common stock issued for services, shares	90,992
Fair value of vested stock options		233,310				233,310
Fair value of vested warrants granted to employees		432,772				432,772
Common stock issued upon exercise of warrants	$ 368	1,470,220				1,470,588
Common stock issued upon exercise of warrants, shares	367,648
Extinguishment of derivative liability		269,368				$ 269,368
Warrant exercises, shares						135,000
Net Loss			(4,048,373)			$ (4,048,373)
Balance at Mar. 31, 2015	$ 7,297	11,288,637	(12,375,234)			(1,079,300)
Balance, shares at Mar. 31, 2015	7,296,892
Amortization of common stock issued to employees with vesting terms		161,936				$ 161,936
Common stock issued upon exercise of options, shares
Common stock issued for services	$ 115	275,885				$ 276,000
Common stock issued for services, shares	114,816
Fair value of vested stock options		286,248				286,248
Fair value of vested warrants granted to employees		182,072				182,072
Issuance of stock and warrants	$ 500	(403,577)				(403,077)
Issuance of stock and warrants, shares	500,000
Extinguishment of derivative liability		99,311				99,311
Common Stock issuable				99,970		$ 99,970
Warrant exercises, shares						275,000
Net Loss			(141,325)			$ (141,325)
Balance at Mar. 31, 2016	$ 7,912	11,890,512	(12,516,559)	99,970		(518,165)
Balance, shares at Mar. 31, 2016	7,911,708
Amortization of common stock issued to employees with vesting terms		129,749				$ 129,749
Amortization of common stock issued to employees with vesting terms, shares	1,436,170
Common stock issued upon exercise of options, shares
Common stock issued for services	$ 312	220,938				$ 221,250
Common stock issued for services, shares	312,500
Fair value of vested stock options		200,315				200,315
Fair value of vested warrants granted to employees		35,014				35,014
Issuance of stock and warrants	$ 2,650	262,350		(99,970)		165,030
Issuance of stock and warrants, shares	2,650,000
Extinguishment of derivative liability		80,278				80,278
Warrant exercises	$ 2,071	349,930				$ 352,001
Warrant exercises, shares	2,070,590					1,760,821
Net Loss			(1,585,924)			$ (1,585,924)
Balance at Sep. 30, 2016	$ 12,945	$ 13,169,086	$ (14,102,483)			$ (920,452)
Balance, shares at Sep. 30, 2016	14,380,968

Condensed Statement of Stockho6

Condensed Statement of Stockholders' Deficit (Parenthetical) - shares	Sep. 30, 2016	Mar. 31, 2016	Mar. 31, 2015
Statement of Stockholders' Equity [Abstract]
Shares issuable	0	999,700	999,700

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows - USD ($)	6 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Mar. 31, 2016	Mar. 31, 2015
Operating activities
Net income (loss)	$ (1,585,924)	$ 719,920	$ (141,325)	$ (4,048,373)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Fair value of vested stock options	200,315	149,556	286,248	233,310
Amortization of common stock issued to employees and director	129,749	93,468
Change in fair value of derivative liability	342,961	(2,312,755)	(2,600,809)	(724,617)
Fair value of common stock issued for services	221,250	176,000	276,000	338,900
Fair value of vested warrants granted to employees	35,014	112,045	182,072	432,772
Fair value of vested common stock issued to employees			161,936	329,511
Cost of warrant modification				961,767
Changes in assets and liabilities:
Accounts receivable	2,460	18,668	31,199	(22,100)
Deposit	(558)
Advance payment on related party lease		(2,300)		10,413
Accounts payable and accrued liabilities	62,133	49,527	110,930	4,092
Accounts payable - related party	13,800	5,900	5,900	(15,100)
Inventory		(954)	2,008	(8,478)
Prepaid expense				8,137
Net Cash Used in Operating Activities	(578,800)	(988,625)	(1,685,841)	(2,499,766)
Investing activities
Acquisition of cash upon acquisition				10,505
Net Cash Provided by Investing Activities				10,505
Financing activities
Proceeds from exercise of warrants, net	352,001			1,470,588
Proceeds from exercise of options				5,000
Proceeds from Common Stock issuable			99,970
Proceeds from sale of common stock and warrants, net	165,030	1,291,574	1,291,574
Net Cash Provided by Financing Activities	517,031	1,291,574	1,391,544	1,475,588
Net increase (decrease) in cash	(61,769)	302,949	(294,297)	(1,013,673)
Cash and cash equivalent - beginning of period	95,433	389,730	389,730	1,403,403
Cash and cash equivalent - end of period	33,664	692,679	95,433	389,730
Cash paid during the period for:
Interest	716	216
Income taxes
Non-Cash Investing and Financing Activities:
Fair value of warrants issued with common stock recorded, as derivative liability		1,694,651	1,694,651	961,767
Extinguishment of derivative liability	$ 80,278		99,311	269,368
Acquisition of accounts receivable upon acquisition				$ 34,495

Business and Basis of Operation

Business and Basis of Operations	6 Months Ended	12 Months Ended
	Sep. 30, 2016	Mar. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business and Basis of Operations	1. BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Vitality Biopharma, Inc. (the “Company”, “we”, “us” or “our”) was incorporated under the laws of the State of Nevada on June 29, 2007. In December 2015, we discovered novel pharmaceutical applications of our glycosylation technology for producing cannabinoid prodrugs and we have recently changed our operational focus towards pharmaceutical development of the cannabinoid prodrugs. On July 15, 2016, the holders of a majority of our outstanding common stock and our Board of Directors approved 1) a name change whereby our name changed from Stevia First Corp. to Vitality Biopharma, Inc., 2) a reverse split of our outstanding common shares whereby each 10 shares of common stock were exchanged for 1 share of common stock and 3) an increase in the number of shares of authorized common stock from 525,000,000 to 1,000,000,000. These changes became effective on July 20, 2016. All share and per share information contained in this Quarterly Report, including these unaudited condensed financial statements, has been adjusted to reflect these changes as if it had occurred in the earliest period presented. Going Concern These financial statements have been prepared on a going concern basis which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying financial statements, for the six months ended September 30, 2016, the Company incurred a net loss of $1,585,924 and utilized $578,800 of cash in operations, and at September 30, 21016, had a stockholders’ deficit of $920,452. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. In addition, the Company’s independent registered public accounting firm, in their report on the Company’s March 31, 2016 audited financial statements, raised substantial doubt about the Company’s ability to continue as a going concern. These financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern. The ability to continue as a going concern is dependent on the Company attaining and maintaining profitable operations in the future and/or raising additional capital to meet its obligations and repay its liabilities arising from normal business operations when they come due. We estimate that we will have sufficient funds to operate the Company through December 31, 2016. These estimates could differ if we encounter unanticipated difficulties, in which case our current funds may not be sufficient to operate our business for that period. In addition, our estimates of the amount of cash necessary to operate our business may prove to be wrong, and we could spend our available financial resources much faster than we currently expect. We do not have any firm commitments for future capital. We will need to raise additional funds in order to continue operating our business and pursue and execute our planned research and development and commercial operations. We do not presently have, nor do we expect in the near future to have, sufficient or consistent revenue to fund our business from our operations, and will need to obtain significant funding from external sources. Since inception, we have funded our operations primarily through equity and debt financings, and we expect to continue to rely on these sources of capital in the future. However, if we raise additional funds by issuing equity or convertible debt securities, our existing stockholders’ ownership will be diluted, and obtaining commercial loans would increase our liabilities and future cash commitments. If we pursue capital through alternative sources, such as collaborations or other similar arrangements, we may be forced to relinquish rights to our proprietary technology or other intellectual property that could result in our receipt of only a portion of any revenue that may be generated from a partnered product or business. Further, these or other sources of capital may not be available on commercially reasonable or acceptable terms when needed, or at all. If we cannot raise the money that we need in order to continue to operate and develop our business, we will be forced to delay, scale back or eliminate some or all of our operations. If any of these were to occur, there is a substantial risk that our business would fail and our stockholders could lose all of their investment. Basis of Presentation of Unaudited Condensed Financial Information The unaudited condensed financial statements of the Company for the six months ended September 30, 2016 and 2015 have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, applied on a consistent basis, and pursuant to the requirements for reporting on Form 10-Q and the requirements of Regulation S-K and Regulation S-X promulgated under the Securities Act of 1933, as amended (the “Securities Act”). Accordingly, they do not include all the information and footnotes required by U.S. GAAP for complete audited financial statements. However, the information included in these financial statements reflects all adjustments (consisting solely of normal recurring adjustments), which are, in the opinion of management, necessary for the fair presentation of the Company’s financial position and the results of operations. Results shown for interim periods are not necessarily indicative of the results to be obtained for a full fiscal year or any future annual or interim period. The balance sheet information as of March 31, 2016 was derived from the audited financial statements as of and for the year ended March 31, 2016 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on June 24, 2016. These financial statements should be read in conjunction with that report. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. The more significant estimates and assumptions by management include, among others, the fair value of equity instruments issued for services, and assumptions used in the valuation of our outstanding derivative liabilities. Accounts Receivable The Company evaluates the collectability of its trade accounts receivable based on a number of factors. In circumstances where the Company becomes aware of a specific customer’s inability to meet its financial obligations to the Company, a specific reserve for bad debts is estimated and recorded, which reduces the recognized receivable to the estimated amount the Company believes will ultimately be collected. In addition to specific customer identification of potential bad debts, bad debt charges are recorded based on the Company’s historical losses and an overall assessment of past due trade accounts receivable outstanding. The allowance for doubtful accounts and returns and discounts is established through a provision reducing the carrying value of receivables. At September 30, 2016, and March 31, 2016, the allowance for doubtful accounts and returns and discounts was approximately $35,500 and $17,517, respectively. Financial Assets and Liabilities Measured at Fair Value The Company accounts for the fair value of financial instruments in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (ASC) topic 820, “Fair Value Measurements and Disclosures” (ASC 820). ASC 820 defines “fair value” as the price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Authoritative guidance provided by the FASB defines the following levels directly related to the amount of subjectivity associated with the inputs to fair valuation of these financial assets: Level 1 Quoted prices in active markets for identical assets or liabilities. Level 2 Inputs, other than quoted prices in active markets, that are observable either directly or indirectly. Level 3 Unobservable inputs based on the Company’s assumptions. The carrying amounts reported in the balance sheets for cash and cash equivalents, accounts payable and accrued liabilities, each qualify as financial instruments and are a reasonable estimate of their fair values because of the short period of time between the origination of such instruments and their expected realization and their current market rate of interest. The Company uses Level 2 inputs for its valuation methodology for the warrant derivative liabilities as their fair values were determined by using a probability weighted average Black-Scholes-Merton pricing model based on various assumptions. The Company’s derivative liabilities are adjusted to reflect fair value at each period end, with any increase or decrease in the fair value being recorded in results of operations as adjustments to fair value of derivatives. At September 30, 2016 and March 31, 2016, the Company’s balance sheet includes the fair value of derivative liabilities of $663,810 and $401,127, respectively, that were measured using level 2 measurements. The Company did not identify any other non-recurring assets and liabilities that are required to be presented in the balance sheets at fair value in accordance with ASC 815. Derivative Financial Instruments The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company uses a probability weighted average Black-Scholes-Merton model to value the derivative instruments at inception and on subsequent valuation dates through the September 30, 2016 reporting date. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date. Revenue Recognition Revenue is measured at the fair value of the consideration received or receivable and represents amounts receivable for products and/or services that have been delivered in the normal course of business, title has passed, the selling price is both fixed and determinable, and collectability is reasonably assured, all of which generally occurs upon shipment of the Company’s product or delivery of the product to the destination specified by the customer. The Company determines whether delivery has occurred based on when title transfers and the risks and rewards of ownership have transferred to the buyer, which usually occurs when the Company ships the products. The Company regularly reviews its customers’ financial positions to ensure that collectability is reasonably assured. Except for warranties, the Company has no post-sales obligations. Stock-Based Compensation The Company periodically issues stock options and warrants to employees and non-employees in non-capital raising transactions, for services and for financing costs. The Company accounts for share-based payments under the guidance as set forth in the Share-Based Payment Topic of the FASB ASC, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, officers, directors, and consultants, including employee stock options, based on estimated fair values. The Company estimates the fair value of share-based payment awards to employees and directors on the date of grant using an option-pricing model, and the value of the portion of the award that is ultimately expected to vest is recognized as expense over the required service period in the Company’s statements of operations. The Company accounts for stock option and warrant grants issued and vesting to non-employees in accordance with the authoritative guidance whereas the value of the stock compensation is based upon the measurement date as determined at either (a) the date at which a performance commitment is reached, or (b) the date at which the necessary performance to earn the equity instruments is complete. Stock-based compensation is based on awards ultimately expected to vest and is reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, as necessary, in subsequent periods if actual forfeitures differ from those estimates. Basic and Diluted Loss Per Share The Company’s computation of earnings (loss) per share (EPS) includes basic and diluted EPS. Basic EPS is calculated by dividing the Company’s net income (loss) available to common stockholders by the weighted average number of common shares during the period. Shares of restricted stock subject to vesting are included in basic weighted average common shares outstanding from the time they vest. Diluted EPS reflects the potential dilution, using the treasury stock method that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the net income (loss) of the Company. In computing diluted EPS, the treasury stock method assumes that outstanding options and warrants are exercised and the proceeds are used to purchase common stock at the average market price during the period. As of September 30, 2016 potentially dilutive securities include options to acquire 2,652,488 shares of common stock and warrants to acquire 9,702,713 shares of common stock. At September 30, 2015 potentially dilutive securities include options to acquire 899,167 shares of common stock and warrants to acquire 2,502,713 shares of common stock. The basic and fully diluted shares for the three and six months ended September 30, 2016 are the same because the inclusion of the potential shares would have had an anti-dilutive effect. Diluted net income per common share for the three and six months ended September 30, 2015 was the same as the exercise price of the potentially dilutive securities was greater than the trading price during the period. Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers In August 2014, the FASB issued Accounting Standards Update No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern In February 2016, the FASB issued Accounting Standards Update (ASU) No. 2016-02, Leases In March 2016, the FASB issued the ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The amendments in this ASU require, among other things, that all income tax effects of awards be recognized in the income statement when the awards vest or are settled. The ASU also allows for an employer to repurchase more of an employee's shares than it can today for tax withholding purposes without triggering liability accounting and allows for a policy election to account for forfeitures as they occur. The amendments in this ASU are effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted for any entity in any interim or annual period. The Company is currently evaluating the expected impact that the standard could have on its financial statements and related disclosures. Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.	1. BUSINESS AND BASIS OF OPERATIONS Stevia First Corp. (the “Company”, “we”, “us” or “our”), was incorporated in the State of Nevada on June 29, 2007 and commenced operations as a mineral exploration company. On October 10, 2011, we completed a merger with our wholly-owned subsidiary, Stevia First Corp., whereby we changed our name from “Legend Mining Inc Going Concern These financial statements have been prepared on a going concern basis which assumes the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The Company has incurred losses since inception and has a stockholders’ deficiency of $518,165 as at March 31, 2016, and further losses are anticipated in the development of its business. These and other factors raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern. The ability to continue as a going concern is dependent on the Company attaining and maintaining profitable operations in the future and/or raising additional capital to meet its obligations and repay its liabilities arising from normal business operations when they come due. We estimate as of March 31, 2016 we will have sufficient funds to operate the business for the next 6 months. We will require additional financing to fund our planned future operations, including the continuation of our ongoing research and development efforts, seeking to license or acquire new assets, and researching and developing any potential patents and any further intellectual property that we may acquire. Further, these estimates could differ if we encounter unanticipated difficulties, in which case our current funds may not be sufficient to operate our business for that period. In addition, our estimates of the amount of cash necessary to operate our business may prove to be wrong, and we could spend our available financial resources much faster than we currently expect. Subsequent to March 31, 2016, we completed a private placement of our common stock and warrants resulting in net proceeds of $265,000, of which proceeds amounting to $99,970 were received in March 2016. We do not have any other firm commitments for future capital. Significant additional financing will be required to fund our planned principal operations in the near term and in future periods, including research and development activities relating to stevia extract production, developing and seeking regulatory approval for any of our stevia product candidates, commercializing any product candidate for which we are able to obtain regulatory approval or certification, seeking to license or acquire new assets or businesses, and maintaining our intellectual property rights and pursuing rights to new technologies. We do not presently have, nor do we expect in the near future to have, significant revenue to fund our business from our operations, and will need to obtain most of our necessary funding from external sources in the near term. Since inception, we have funded our operations primarily through equity and debt financings, and we expect to continue to rely on these sources of capital in the future. However, if we raise additional funds by issuing equity or convertible debt securities, our existing stockholders’ ownership will be diluted, and obtaining commercial loans would increase our liabilities and future cash commitments. If we pursue capital through alternative sources, such as collaborations or other similar arrangements, we may be forced to relinquish rights to our proprietary technology or other intellectual property and could result in our receipt of only a portion of any revenue that may be generated from a partnered product or business. Further, these or other sources of capital may not be available on commercially reasonable or acceptable terms when needed, or at all. If we cannot raise the money that we need in order to continue to develop our business, we will be forced to delay, scale back or eliminate some or all of our proposed operations. If any of these were to occur, there is a substantial risk that our business would fail and our stockholders could lose all of their investment.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Use of Estimates and Assumptions The preparation of financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. The more significant estimates and assumptions by management include, among others, reserves for accounts receivable, the fair value of equity instruments issued for services, and input assumptions used in the valuation of derivative liabilities. Revenues Revenue is measured at the fair value of the consideration received or receivable and represents amounts receivable for products and/or services that have been delivered in the normal course of business, title has passed, the selling price is both fixed and determinable, and collectability is reasonably assured, all of which generally occurs upon shipment of the Company’s product or delivery of the product to the destination specified by the customer. The Company determines whether delivery has occurred based on when title transfers and the risks and rewards of ownership have transferred to the buyer, which usually occurs when the Company ships the products. The Company regularly reviews its customers’ financial positions to ensure that collectability is reasonably assured. Except for warranties, the Company has no post-sales obligations. Accounts Receivable The Company evaluates the collectability of its trade accounts receivable based on a number of factors. In circumstances where the Company becomes aware of a specific customer’s inability to meet its financial obligations to the Company, a specific reserve for bad debts is estimated and recorded, which reduces the recognized receivable to the estimated amount the Company believes will ultimately be collected. In addition to specific customer identification of potential bad debts, bad debt charges are recorded based on the Company’s historical losses and an overall assessment of past due trade accounts receivable outstanding. The allowance for doubtful accounts and returns and discounts is established through a provision reducing the carrying value of receivables. At March 31, 2016 and 2015, the allowance for doubtful accounts and returns and discounts was approximately $17,500 and $2,500, respectively. Financial Assets and Liabilities Measured at Fair Value The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis. Financial assets recorded at fair value in the balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value. Authoritative guidance provided by FASB defines the following levels directly related to the amount of subjectivity associated with the inputs to fair valuation of these financial assets: Level 1 Quoted prices in active markets for identical assets or liabilities. Level 2 Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly. Level 3 Unobservable inputs based on the Company’s assumptions. The fair value of the derivative liabilities of $401,127 and $1,406,596 at March 31, 2016 and 2015, respectively, were valued using Level 2 inputs. The carrying value of cash and accounts payable and accrued liabilities approximates their fair value because of the short maturity of these instruments. Unless otherwise noted, it is management’s opinion that the Company is not exposed to significant interest, currency or credit risks arising from these financial instruments. Derivative Financial Instruments The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company uses a probability weighted average Black-Scholes-Merton models to value the derivative instruments at inception and on subsequent valuation dates through the March 31, 2016, reporting date. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Income Taxes The Company follows the asset and liability method of accounting for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the estimated tax consequences attributable to differences between the financial statement carrying values and their respective income tax basis (temporary differences). The effect on deferred income tax assets and liabilities of a change in tax rates is recognized as income (loss) in the period that includes the enactment date. Stock-Based Compensation The Company periodically issues stock options and warrants to employees and non-employees in non-capital raising transactions, for services and for financing costs. The Company accounts for share-based payments under the guidance as set forth in the Share-Based Payment Topic of the FASB Accounting Standards Codification (“ASC”), which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, officers, directors, and consultants, including employee stock options, based on estimated fair values. The Company estimates the fair value of share-based payment awards to employees and directors on the date of grant using a Black-Scholes-Merton option-pricing model, and the value of the portion of the award that is ultimately expected to vest is recognized as expense over the required service period in the Company’s statements of operations. The Company accounts for stock option and warrant grants issued and vesting to non-employees in accordance with the authoritative guidance whereas the value of the stock compensation is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) the date at which the necessary performance to earn the equity instruments is complete. Stock-based compensation is based on awards ultimately expected to vest and is reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, as necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company periodically issues unvested (“restricted”) shares of its common stock to employees as equity incentives. The Company’s restricted stock vests upon the satisfaction of a recipient’s service condition, which is satisfied over a period of number of years. The restricted shares vest over certain period and remain subject to forfeiture if vesting conditions are not met. The Company values the shares based on the price per share of the Company’s shares at the date of grant and recognizes the value as compensation expense ratably over the vesting period. Basic and Diluted Loss Per Share The Company computes loss per share in accordance with ASC Topic 260, “Earnings per Share” which requires presentation of both basic and diluted earnings per share on the face of the statement of operations. Basic loss per share is computed by dividing the net loss applicable to common stockholders by the weighted average number of outstanding common shares during the period. Diluted loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued. Diluted loss per share excludes all potential common shares if their effect is anti-dilutive. The following potentially dilutive shares were excluded from the shares used to calculate diluted earnings per share as their inclusion would be anti-dilutive: March 31, 2016 2015 Options 909,167 632,500 Warrants 2,002,713 1,212,713 Total 2,911,880 1,845,213 Research and Development Research and development costs consist primarily of fees paid to consultants and outside service providers, patent fees and costs, and other expenses relating to the acquisition, design, development and testing of the Company’s treatments and product candidates. Research and development costs are expensed as incurred over the life of the underlying contracts on the straight-line basis, unless the achievement of milestones, the completion of contracted work, or other information indicates that a different expensing schedule is more appropriate. The Company reviews the status of its research and development contracts on a quarterly basis. Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers In August 2014, the FASB issued Accounting Standards Update No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern In November 2014, the FASB issued Accounting Standards Update No. 2014-16, Determining Whether the Host Contract in a Hybrid Financial Instrument Issued in the Form of a Share Is More Akin to Debt or to Equity. The amendments in ASU 2014-6 do not change the current criteria in U.S. GAAP for determining when separation of certain embedded derivative features in a hybrid financial instrument is required. The amendments clarify that an entity should consider all relevant terms and features, including the embedded derivative feature being evaluated for bifurcation, in evaluating the nature of the host contract. ASU 2014-6 applies to all entities that are issuers of, or investors in, hybrid financial instruments that are issued in the form of a share and is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. Early adoption is permitted. The Company is currently evaluating the expected impact that the standard could have on its financial statements and related disclosures. In February 2016, the FASB issued Accounting Standards Update (ASU) No. 2016-02, Leases Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

Acquisition from Related Party

Acquisition from Related Party	12 Months Ended
	Mar. 31, 2016
Business Combinations [Abstract]
Acquisition from Related Party	3. ACQUISITION FROM RELATED PARTY On May 16, 2014, the Company entered into an Asset Purchase Agreement with Percipio Biosciences, Inc. (“Percipio”), a Delaware corporation, to purchase certain assets of Percipio for $50,000. The Company’s Chief Executive Officer, Robert Brooke, owned 20% of Percipio. The acquisition of the assets has been accounted for as a purchase in accordance with ASC Topic 805 Business Combinations and the assets have been included in the Company’s financial statements since May 16, 2014. The purchase price was allocated to current assets based on their fair value as determined by management. At March 31, 2016, $11,950 of the purchase price remains unpaid and is included in accounts payable on the accompanying balance sheet. The Company has determined that the acquisition is not a material acquisition and accordingly, no pro-forma information has been presented. In conjunction with the Percipio asset purchase, the Company entered into written employment agreement with Dr. Fang Lu, majority owner and President of Percipio, under which he now serves as Senior Scientist for the Company. Dr. Lu’s employment agreement commenced on May 17, 2014 and is terminable at any time at the option of Dr. Lu or the Company. Under the employment agreement, Dr. Lu is entitled to an annual salary of $95,000.

Derivative Liability

Derivative Liability	6 Months Ended	12 Months Ended
	Sep. 30, 2016	Mar. 31, 2016
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Liability	2. DERIVATIVE LIABILITY Under authoritative guidance by the FASB on determining whether an instrument (or embedded feature) is indexed to an entity’s own stock, instruments which do not have fixed settlement provisions are deemed to be derivative instruments. The warrants issued to purchasers and placement agent in June 2013 and September 2014, and the warrants issued to investors in May 2015, do not have fixed settlement provisions because their exercise prices will be lowered if the Company issues securities at lower prices in the future or have other variable provisions. The Company was required to include the reset provisions in order to protect the holders of the warrants from the potential dilution associated with future financings, and a fundamental transaction provision, which require a revaluation of the liabilities. In accordance with the FASB authoritative guidance, the warrants have been characterized as derivative liabilities to be re-measured at the end of every reporting period with the change in value reported in the statement of operations. As of March 31, 2016 and September 30, 2016, the derivative liabilities were valued using a probability weighted average Black-Scholes-Merton pricing model with the following assumptions: Warrants: September 30, 2016 March 31, 2016 Exercise Price $ 2.00 - 4.25 $ 3.00 - 4.50 Stock Price $ 1.08 $ 0.70 Risk-free interest rate 0.59 - 0.98 % 0.19 - 1.04 % Expected volatility 127.45 % 105.06 - 124.77 % Expected life (in years) 1.0 - 3.7 years 0.1 - 4.2 years Expected dividend yield 0 0 Fair Value: $ 663,810 $ 401,127 The risk-free interest rate was based on rates established by the Federal Reserve Bank. The Company uses the historical volatility of its common stock to estimate the future volatility for its common stock. The expected life of the warrants was determined by the expiration dates of the warrants. The expected dividend yield was based on the fact that the Company has not paid dividends to its common stockholders in the past and does not expect to pay dividends to its common stockholders in the future. At March 31, 2016, the fair value of the derivative liabilities was $401,127. During the six months ended September 30, 2016, derivative liabilities of $80,278 were extinguished that were related to warrants that expired. In addition the Company recorded an increase in fair value of the derivative liabilities of $342,961. At September 30, 2016, the fair value of the derivative liabilities was $663,810.	4. DERIVATIVE LIABILITY The FASB has issued authoritative guidance whereby instruments which do not have fixed settlement provisions are deemed to be derivative instruments. Certain warrants issued to investors and placement agents (described in Note 5 and Note 6) do not have fixed settlement provisions because their exercise prices will be lowered if the Company issues securities at lower prices in the future. In accordance with the FASB authoritative guidance, the warrants have been characterized as derivative liabilities to be re-measured at the end of every reporting period with the change in value reported in the statement of operations. At the applicable dates of issuance and as of March 31, 2015 and March 31, 2016, the derivative liabilities were valued using a probability weighted average Black-Scholes-Merton pricing model with the following assumptions: Date of Modification September 24, 2014 March 31, 2015 Upon Issuance May 11, 2015 March 31, 2016 Exercise Price $ 4.00 – 4.50 $ 3.40 - 4.50 $ 3.50 - 4.50 $ 3.00 – 4.50 Stock Price $ 4.20 $ 3.80 $ 2.90 $ 0.70 Risk-free interest rate 1.78 - 2.0 % 0.41 - 1.25 % 0.17 - 1.59 % 0.19 – 1.04 % Expected volatility 84.45 % 76.26 % 76.26 - 107.5 % 105.06 - 124.77 % Expected life (in years) 0.01 – 5.0 years 2.50 - 4.5 years 0.75 – 5.0 years 0.1 – 4.2 years Expected dividend yield 0.00 0.00 0.00 0.00 Fair Value: $ 961,767 $ 1,406,596 $ 1,694,651 $ 401,127 The risk-free interest rate was based on rates established by the Federal Reserve Bank. The Company uses the historical volatility of its common stock to estimate the future volatility for its common stock. The expected life of the warrants was determined by the expiration date of the warrants. The expected dividend yield was based on the fact that the Company has not paid dividends to its common stockholders in the past and does not expect to pay dividends to its common stockholders in the future. On September 10, 2014, certain terms of certain of the Company’s warrants were modified in connection with an early exercise offer made to the warrant holders, and the incremental change in their fair values of $21,218 was accounted for as an increase in the fair value of the derivative liabilities as of the date of modification and recorded as a cost to induce exercise of the warrants. Also, as part of the terms of the early exercise offer, the Company issued to such warrant holders new, replacement warrants with an aggregate fair value at their issue date of $940,549, which was accounted for as a derivative liability at the issue date (described in Note 7). All of the warrants subject to the early exercise offer, which were accounted for as derivative liabilities, were exercised in connection with such offer, and as such their corresponding fair value at the exercise date of $269,368 was extinguished from the derivative liabilities balance. During the year ended March 31, 2015, we recognized a change in fair value of the derivative liability of $724,617. As of March 31, 2015, the aggregate fair value of the derivative liabilities was $1,406,596. In May 2015, we recognized additional derivative liabilities of $1,694,651 related to the warrants issued in conjunction with the sale of the Company’s common stock (described in Note 5). For the fiscal year ended March 31, 2016, the Company recognized a change in fair value of the derivative liability of $2,600,809. As of March 31, 2016, the aggregate fair value of the derivative liabilities was $401,127.

Stockholders' Equity Deficiency

Stockholders' Equity Deficiency	6 Months Ended	12 Months Ended
	Sep. 30, 2016	Mar. 31, 2016
Stockholders' Equity Note [Abstract]
Stockholders' Equity Deficiency	3. EQUITY Equity Financing In May 2016, the Company entered into a securities purchase agreement providing for the issuance and sale by the Company, in a private placement, of units including 2,650,000 shares of the Company’s common stock (the “Shares”) and Warrants to purchase 7,950,000 shares of the Company’s common stock (the “Warrants”), at a price of $0.10 per Share. The Warrants have an exercise price of $0.17 per share and expire February 4, 2017. The offering closed on May 4, 2016, and aggregate proceeds to the Company from the sale of the Shares and Warrants was $265,000. $165,030 of the proceeds was received in the current period and $99,970 was received prior to April 1, 2016 and had been reflected as common stock issuable at March 31, 2016. Common stock issued to employees for services with vesting terms The Company has issued shares of common stock to employees and directors that vest over time. The fair value of these stock awards were based on the market price of the Company’s common stock at the dates granted, and are amortized over vesting terms ranging up to three years. During the six months ended September 30, 2016, the Company issued an aggregate of 1,436,170 shares of its common stock to one officer and one director. The aggregate fair value of these awards was approximately $718,000, which will amortized over the 1.75 year vesting term of the awards. At March 31, 2016, the accumulated vested balance of stock awards was $611,216. During the six months ended September 30, 2016, the fair value of stock awards that vested was $129,749. At September 30, 2016, the accumulated vested balance of the stock awards $740,965. At September 30, 2016, the amount of unvested compensation related to these awards is approximately $614,000, and will be recorded as expense over 1.4 years as the shares vest. Shares of restricted stock granted above are subject to forfeiture to the Company or other restrictions that will lapse in accordance with a vesting schedule determined by our Board. In the event a recipient’s employment or service with the Company terminates, any or all of the shares of common stock held by such recipient that have not vested as of the date of termination under the terms of the restricted stock agreement are forfeited to the Company in accordance with such restricted grant agreement. The following table summarizes restricted common stock activity: Number of Shares Non-vested shares, March 31, 2016 175,833 Granted 1,436,170 Vested (2,500 ) Forfeited (2,500 ) Non-vested shares, September 30, 2016 1,607,003	5. STOCKHOLDERS’ DEFICIENCY Equity financing In May 2015, the Company entered into a Securities Purchase Agreement with seven purchasers for the sale of an of aggregate of 500,000 shares of the Company’s common stock (collectively, the “Shares”), and warrants to purchase an aggregate of 1,250,001 shares of the Company’s common stock for total gross proceeds of $1,500,000, or a sales price of $3.00 per share (the “Offering”). The Offering closed on May 11, 2015. The Company incurred $208,426 direct costs, fees and expenses in connection with the Offering, resulting in net cash proceeds to the Company of $1,291,574. The warrants to purchase an aggregate of 1,250,001 issued to the purchasers in the Offering were issued in three tranches: Series A Warrants to purchase up to an aggregate of 500,000 shares of the Company’s common stock, with exercise price of $4.50 per share, and a term of 5 years; Series B Warrants to purchase up to an aggregate of 500,000 shares of the Company’s common stock, with exercise price of $3.50 per share, and a term of 9 months; and Series C Warrants to purchase up to an aggregate of 250,000 shares of the Company’s common stock , with exercise price of $4.00 per share, and a term of 1 year; all of which are exercisable immediately (the Series A Warrants, the Series B Warrants and the Series C Warrants, collectively, the “Warrants”). The Company also issued warrants to purchase up to 40,000 shares of the Company’s common stock (the “Placement Agent Warrants”) to H.C. Wainwright& Co., LLC as placement agent to the Offering. The Placement Agent Warrants have an exercise price of $3.75 per share, a term of 5 years, and are exercisable immediately. The exercise price of the Series A Warrants granted to the purchasers of the Offering includes an anti-dilution provision that allows for the automatic reset of the exercise price upon any future sale of the Company’s common stock, warrants, options, convertible debt or any other equity-linked securities at an issuance, exercise or conversion price below the current exercise price of the warrants, provided that the exercise price shall not be reduced to less than $2.00 per share. Additionally, all of the Warrants granted to the purchasers of the Offering and the Placement Agent Warrants are subject to provision for certain fundamental transactions. The Company considered the current FASB guidance of “Determining Whether an Instrument Indexed to an Entity’s Own Stock” and determined that the exercise prices of the Warrants and the Placement Agent Warrants were not fixed amounts because they are subject to fluctuation based on the occurrence of future offerings or events, and certain fundamental transactions. As a result, the Company determined that the Warrants and the Placement Agent Warrants are not considered indexed to the Company’s own stock and characterized the initial fair value of these warrants as derivative liabilities upon issuance. The Company determined the aggregate initial fair value of the Warrants and the Placement Agent Warrants in the Offering to be $1,694,651 at issuance valued using a probability weighted average Black-Scholes-Merton pricing model. For financial statement purposes, the amount of the derivative liability created from the issuance of the Warrants and the Placement Agent Warrants of $1,694,651 has been offset to the net cash proceeds received of $1,291,574, resulting in a net reduction of additional paid-in capital of $408,077 from the sale of the Shares of common stock and Warrants. Common stock issued to employees for services with vesting terms The Company has issued the following shares of common stock to employees and directors that vest over time: ● In July and August 2012, the Company issued an aggregate of 70,000 shares of its common stock to employees and a director of the Company, with aggregate fair value of $189,000 at grant date, and vesting over a period ranging from 16 months to 60 months from the date of grant under the Company’s stock option and incentive plan (the “2012 Stock Incentive Plan”). ● In July 2013, the Company issued 10,000 shares of its common stock to an employee of the Company with fair value of $36,000 at grant date and vesting over a period of 31 months from the date of grant under the Company’s 2012 Stock Incentive Plan. ● In conjunction with the Percipio asset purchase (see Note 3) entered into by the Company on May 2014, the Company entered into an employment agreement with a new employee, pursuant to which the Company granted 10,000 shares of its common stock with fair value of $38,000 at grant date. The 10,000 shares of stock is vesting over a period of 24 months from the date of grant under the Company’s 2012 Stock Incentive Plan. ● In conjunction with the Distribution and License Agreements (see Note 9) entered into by the Company in August 2014, the Company entered into employment agreements with two new employees, pursuant to which the Company granted an aggregate of 140,000 shares of its common stock, with aggregate fair value of $420,000 at grant date. Of these 140,000 shares of stock, 40,000 vested immediately, and the remaining 100,000 are vesting over periods ranging from 12 months to 36 months from the date of grant. An aggregate of 100,000 shares of the Company’s restricted common stock will also be issued and will vest upon achievement certain milestones, for which the Company will account for their costs at the time their issuance becomes probable. These shares of common stock were valued based upon the market price of the Company’s common stock at the dates of grant and determined the aggregate fair values to be of approximately $683,000. The allocable portion of the aggregate fair values of these shares of common stock that vested during the years ended March 31, 2016 and 2015 amounted to $161,936 and $329,511, respectively, and were recognized as expense in the accompanying statements of operations during the years then ended. As of March 31, 2016, approximately $86,000 of these awards remains unvested and will be amortized as compensation costs in future years. Shares of restricted stock granted above are subject to forfeiture to the Company or other restrictions that will lapse in accordance with a vesting schedule determined by our Board. In the event a recipient’s employment or service with the Company terminates, any or all of the shares of common stock held by such recipient that have not vested as of the date of termination under the terms of the restricted stock agreement are forfeited to the Company in accordance with such restricted grant agreement. The Company reclassified $149,714 from unvested, unissued common stock to additional paid-in capital relating to the unvested portion of vested shares granted as of the prior year ended March 31, 2014, to make its presentation of stockholders’ deficiency reflect the transaction more appropriately. There was no net effect on stockholders’ deficiency. Common stock issued for services During the year ended March 31, 2015, the Company issued an aggregate of 79,098 shares of the Company’s common stock to consultants as payment for services and recorded an expense of $294,100 based on the closing market price of our common stock on the date of the issuance. These shares were issued outside of the 2012 Stock Incentive Plan. In December 2014, the Company issued 7,895 shares of common stock under the 2012 Stock Incentive Plan to a consultant under the terms of a consulting agreement and recorded an expense of $30,000 based on the closing market price of our common stock on the date of issuance. In March 2015, the Company also issued 4,000 shares of common stock under the 2012 Stock Incentive Plan, to an employee and recorded an expense of $14,800 based on the closing market price of our common stock on the date of issuance. In May 2015, pursuant to the terms of certain consulting agreement, the Company issued an aggregate of 32,500 shares of the Company’s common stock to two consultants as payment for services and recorded an expense of $115,000 based on the fair value of the Company’s common stock at the issuance dates. In July 2015, we issued a total of 31,000 shares of our common stock to two consultants in exchange for services and recorded an expense of $61,000. These shares were issued outside of the 2012 Stock Incentive Plan. In October and November 2015, pursuant to the terms of a certain consulting agreement, the Company issued an aggregate of 51,316 shares of the Company’s common stock to a consultant as payment for services valued at $100,000. These shares were issued outside of the 2012 Stock Incentive Plan.

Stock Options

Stock Options	6 Months Ended	12 Months Ended
	Sep. 30, 2016	Mar. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock Options	4. STOCK OPTIONS During the six months ended September 30, 2016, the Company granted to employees options to purchase an aggregate of 1,618,262 shares of the Company’s common stock with exercise price of $0.50 per share, that expire ten years from the date of grant, and all have vesting period of 24 months. The fair value of each option award was estimated on the date of grant using the Black-Scholes option pricing model based on the following assumptions: (i) volatility rate of 126.34%, (ii) discount rate of 1.60 %, (iii) zero expected dividend yield, and (iv) expected life of 6 years, which is the average of the term of the options and their vesting periods. The total fair value of the option grants to employees at their grant dates was approximately $775,000. During the six months ended September 30, 2016, the Company also granted to two consultants options to purchase 142,559 shares of the Company’s common stock with exercise prices of per share $0.50 and $0.96, respectively, both option grants expire in ten years from date of grant, and both have vesting period of 24 months. The fair value of these options granted to the consultants was estimated using the Black-Scholes option pricing model based on the following assumptions: (i) volatility rate between 126.34%, (ii) discount rate of 1.36%, (iii) zero expected dividend yield, and (iv) expected life of 10 years. The total fair value of the option grants to the consultants at their grant dates was approximately $146,000. Pursuant to the terms of the 2012 Stock Incentive Plan, the exercise price for all equity awards issued under the 2012 Stock Incentive Plan is based on the market price per share of the Company’s common stock on the date of grant of the applicable award. A summary of the Company’s stock option activity for the six months ended September 30, 2016 is presented below: Shares Weighted Average Exercise Price Balance at March 31, 2016 907,500 $ 3.30 Granted 1,760,821 0.51 Exercised - - Expired (225,000 ) 3.73 Cancelled (15,833 ) 3.40 Balance outstanding at September 30, 2016 2,427,488 $ 1.08 Balance exercisable at September 30,2016 524,167 $ 2.64 At September 30, 2016, options to purchase common shares were outstanding as follows: Number of options Weighted Average Exercise Price Weighted Average Grant-date Stock Price Options Outstanding, September 30, 2016 1,710,821 $ 0.50 $ 0.5 50,000 $ 0.96 $ 0.96 130,000 $ 1.00 $ 10.00 10,000 $ 1.50 $ 0.40 287,500 $ 2.00 - 2.70 $ 2.00 - 2.70 130,000 $ 3.10 - 3.80 $ 3.10 - 3.80 49,167 $ 4.00 - 4.70 $ 4.00 - 4.70 60,000 $ 5.10 $ 5.10 2,427,488 Options Exercisable, September 30,2016 130,000 $ 1.00 $ 10.00 2,500 $ 1.50 $ 0.40 177,500 $ 2.00 - 2.70 $ 2.00 - 2.70 108,334 $ 3.10 - 3.80 $ 3.10 - 3.80 45,833 $ 4.00 - 4.70 $ 4.00 - 4.70 60,000 $ 5.10 $ 5.10 524,167 During the six months ended September 30, 2016 and 2015, we expensed total stock-based compensation related to vesting stock options of $200,315 and $149,556, respectively, and the remaining unamortized cost of the outstanding stock options at September 30, 2016 was $1,045,044. This cost will be amortized on a straight line basis over a weighted average remaining vesting period of 2 years and will be adjusted for subsequent changes in estimated forfeitures. Future option grants will increase the amount of compensation expense that will be recorded. The intrinsic values of all outstanding and exercisable stock options at September 30, 2016 were approximately $1,000,000 and $0, respectively.	6. STOCK OPTIONS Year Ended March 31, 2015 During the year ended March 31, 2015, the Company granted to employees options to purchase an aggregate of 112,500 shares of the Company’s common stock that expire ten years from the date of grant and have vesting periods ranging from zero to 36 months. The fair value of each option award was estimated on the date of grant using the Black-Scholes option pricing model based on the following assumptions: (i) volatility rate of 81.84%, (ii) discount rate of 1.62 %, (iii) zero expected dividend yield, and (iv) expected life of 5 years, which is the average of the term of the options and their vesting periods. The total fair value of the option grants to employees at their grant dates was approximately $300,000. During the year ended March 31, 2015, the Company also granted to three consultants options to purchase 22,500 shares of the Company’s common stock that expire between five and ten years from date of grant and have vesting periods ranging from is 0 to 36 months. The fair value of these options granted to the consultants was estimated using the Black-Scholes option pricing model based on the following assumptions: (i) volatility rate of 76.26%, (ii) discount rate of 2.17 %, (iii) zero expected dividend yield, and (iv) expected life of 5 years. The total fair value of the option grants to the consultants at their grant dates was approximately $88,000. In April 2014, 5,000 options were exercised by a consultant at an exercise price of $1.00 per share or total proceeds to the Company of $5,000. Year Ended March 31, 2016 During the year ended March 31, 2016, the Company granted to employees options to purchase an aggregate of 137,500 shares of the Company’s common stock that expire ten years from the date of grant and have vesting periods ranging from zero to 36 months. The fair value of each option award was estimated on the date of grant using the Black-Scholes option pricing model based on the following assumptions: (i) volatility rate of 76.26%, (ii) discount rate of 2.19 %, (iii) zero expected dividend yield, and (iv) expected life of 5 years, which is the average of the term of the options and their vesting periods. The total fair value of the option grants to employees at their grant dates was approximately $233,000. During the year ended March 31, 2016, the Company also granted to five consultants options to purchase 140,000 shares of the Company’s common stock that expire between three and ten years from date of grant and have vesting periods ranging from is 0 to 36 months. The fair value of these options granted to the consultants was estimated using the Black-Scholes option pricing model based on the following assumptions: (i) volatility rate between 76.26% to 107.51%, (ii) discount rate of 2.17%, (iii) zero expected dividend yield, and (iv) expected life of 5 years. The total fair value of the option grants to the consultants at their grant dates was approximately $131,000. A summary of the Company’s stock option activity during the fiscal years ended March 31, 2015 and 2016 is as follows: Shares Weighted Average Exercise Price Balance at March 31, 2014 515,000 $ 2.60 Granted 135,000 Exercised (5,000 ) Cancelled (12,500 ) Balance outstanding at March 31, 2015 632,500 $ 3.30 Granted 275,000 Exercised - Cancelled - Balance outstanding at March 31, 2016 907,500 $ 3.30 Balance exercisable at March 31,2016 679,376 $ 3.20 A summary of the Company’s stock options outstanding as of March 31, 2016 is as follows: Number of Options Weighted Average Exercise Price Weighted Average Grant-date Stock Price Options Outstanding, March 31, 2016 130,000 $ 1.00 $ 10.00 10,000 1.50 1.50 287,500 $ 2.00 - 2.70 $ 2.00 - 2.70 220,000 $ 3.10 - 3.80 $ 3.10 - 3.80 199,167 $ 4.00 - 4.70 $ 4.00 - 4.70 60,000 $ 5.10 $ 5.10 907,500 Options Exercisable, March 31, 2016 130,000 $ 1.00 $ 10.00 123,750 $ 2.00 - 2.70 $ 2.00 - 2.70 171,667 $ 3.10 - 3.80 $ 3.10 - 3.80 193,959 $ 4.00 - 4.70 $ 4.00 - 4.70 60,000 $ 5.10 $ 5.10 679,376 During the years ended March 31, 2016 and 2015, we expensed total stock-based compensation related to stock options of $286,248 and $233,310, respectively, and the remaining unamortized cost of the outstanding stock-based awards at March 31, 2016 was approximately $345,000. This cost will be amortized on a straight line basis over a weighted average remaining vesting period of 2 years and will be adjusted for subsequent changes in estimated forfeitures. Future option grants will increase the amount of compensation expense that will be recorded. The outstanding stock options had no intrinsic value at March 31, 2016.

Warrants

Warrants	6 Months Ended	12 Months Ended
	Sep. 30, 2016	Mar. 31, 2016
Warrants and Rights Note Disclosure [Abstract]
Warrants	5. WARRANTS At September 30, 2016, warrants to purchase common shares were outstanding as follows: Shares Weighted Average Exercise Price Balance at March 31, 2016 2,002,718 $ 3.50 Granted 7,950,000 0.17 Exercised (2,070,590 ) 0.17 Expired (250,000 ) $ 4.00 Balance outstanding and exercisable at September 30, 2016 7,632,128 $ 0.65 Warrants issued in equity financing (see Note 3) In May 2016, the Company issued warrants to purchase up to an aggregate of 7,950,000 shares of the Company’s common stock in conjunction with a securities purchase agreement for the sale of shares of the Company’s common stock and warrants. The warrants have an exercise price of $0.17 per share and expire on February 4, 2017. Warrants issued to employees On August 25, 2014, we entered into employment agreements with two employees, pursuant to which these employees received warrants to purchase an aggregate of 440,000 shares of the Company’s common stock (see Note 7). The warrants have an exercise price of $3.00, and a term of ten years from issue date. Warrants to purchase 80,000 shares of common stock vested immediately and their grant date fair value of $201,680 was recorded as an expense in 2014. Warrants to purchase 200,000 shares of common stock with a fair value of $504,204 upon grant date are being amortized over their vesting terms, which ranges from one year to three years. The balance of 160,000 warrants vest upon the achievement of certain milestones, as defined, none of which have been met through September 30, 2016. At March 31, 2016, the accumulated amortization of the vested fair value for these warrants was $614,846. During the six months ended September 30, 2016, amortization of vested warrants was $35,014, and at September 30, 2016, the accumulated amortization for vested warrants was $649,860. During the six months ended September 30, 2016, the Company received $352,000 of proceeds from holders of warrants to acquire 2,070,590 shares of common stock. The aggregate intrinsic value of all of the outstanding and exercisable warrants at September 30, 2016 and March 31, 2016 was approximately $5,350,263 and $0, respectively.	7. WARRANTS A summary of warrants to purchase common stock issued during the fiscal years ended March 31, 2015 and 2016 is as follows: Shares Weighted Average Exercise Price Balance outstanding at March 31, 2014 772,717 $ 4.10 Granted 807,648 3.70 Exercised (367,647 ) 4.00 Cancelled - - Balance outstanding at March 31, 2015 1,212,718 $ 3.90 Granted 1,290,000 3.40 Exercised - - Expired (500,000 ) 3.50 Balance outstanding at March 31, 2016 2,002,718 $ 3.50 Balance exercisable at March 31, 2016 2,002,718 $ 3.50 On September 9, 2014, we offered the holders of 367,647 warrants the right to exercise all of those warrants, for an aggregate of 367,647 shares of our common stock, based on the terms of an early exercise offer wherein such warrants became exercisable at a reduced exercise price of $4.00 per share and new warrants would be issued to such investors, so long as the exercise thereof occurred on or before September 10, 2014. All purchasers acted on the early exercise offer and we issued 367,647 shares of our common stock for net proceeds to us of $1,470,589. We determined that the modification of the exercise price of the warrants from $4.20 per share to $4.00 per share should be recorded as a cost to induce the exercise of the warrants. As such, we recognized the difference of $21,218 between the fair value of the warrants before and after the modification as a cost in the accompanying statements of operations for the year ended March 31, 2015. In conjunction with the early exercise offer, we issued to the warrant holders who acted on such offer new, replacement warrants to purchase an additional 367,647 shares of our common stock. The terms and conditions of the replacement warrants are the same as the terms of the originally issued warrants, except that: (a) the initial exercise date is September 10, 2014 rather than June 28, 2013; (b) the replacement warrants have an exercise term of five years rather than nine months; (c) the exercise price of the replacement warrants is $4.50 per share (subject to anti-dilution and other adjustments as described below and a floor exercise price of $2.00 per share); and (d) the replacement warrants and the shares of common stock underlying such warrants are not registered under the Securities Act and are restricted securities. The new warrants are exercisable immediately upon issuance. These replacement warrants also provide for the adjustment of the exercise price and/or number of shares issuable upon exercise thereof in connection with stock dividends and splits, subsequent rights offerings, pro rata distributions to the Company’s common stockholders and subsequent equity sales by the Company at an effective price lower than the then-current exercise price of the replacement warrants. We determined that the fair value of these replacement warrants at their issue date of $940,549 was recorded as a cost to induce the exercise of the originally issued nine-month warrants in the accompanying statements of operations for the year ended March 31, 2015. In May 2015, the Company granted 500,000 Series A warrants, 500,000 Series B warrants and 250,000 Series C warrants in connection with an offering of the Company’s common stock for cash. Each Series A Warrant has an exercise price of $4.50 per share, was immediately exercisable, and expires on the five year anniversary of the date of issuance. Each Series B Warrant has an exercise price of $3.50 per share, was immediately exercisable, and expired on the nine month anniversary of the date of issuance. Each Series C Warrant has an exercise price of $4.00 per share, was immediately exercisable, and will expire on the one year anniversary of the date of issuance. The Company also issued Placement Agent Warrants to purchase up to 40,000 shares of the Company’s common stock to H.C. Wainwright. The Placement Agent Warrants have an exercise price of $3.75 per share, a term of 5 years, and are exercisable immediately. The exercise price of the Series A Warrants granted to the purchasers of the Offering includes an anti-dilution provision that allows for the automatic reset of the exercise price upon any future sale of the Company’s common stock, warrants, options, convertible debt or any other equity-linked securities at an issuance, exercise or conversion price below the current exercise price of the warrants, provided that the exercise price shall not be reduced to less than $2.00 per share. Additionally, all of the Warrants granted to the purchasers of the Offering and to the placement agent are subject to provision for certain fundamental transactions. In consideration of applicable guidance, the Company has determined that none of the warrants are considered indexed to the Company’s own stock, since the exercise prices of the warrants are subject to fluctuation based on the occurrence of future offerings or events and are not a fixed amount, and therefore characterizes the fair value of these warrants as derivative liabilities (See Note 3). In consideration of applicable guidance, the Company has determined that the warrants are not considered indexed to the Company’s own stock, since the exercise prices of the warrants are subject to fluctuation based on the occurrence of future offerings or events and are not a fixed amount, and therefore characterized the fair value of these warrants of $401,127 as a derivative liability upon issuance (See Note 4). Warrants issued to employees On August 25, 2014, we entered into employment agreements with two new employees, pursuant to which, these employees became entitled to receive warrants to purchase an aggregate of 440,000 shares of the Company’s common stock. These warrants have an exercise price of $3.00, and a term of ten years from issue date. Vesting terms of these warrants are as follows: (i) warrants to purchase 80,000 shares of common stock vested immediately at their grant date, (ii) warrants to purchase 200,000 shares of common stock have vesting terms ranging from one year to three years, and (iii) warrants to purchase 160,000 shares of common stock vest upon achievement of certain milestones under the distribution agreement (See Note 9). During the years ended March 31, 2016 and 2015, we expensed total stock-based compensation related to the vesting of these warrants of $182,072 and $432,772, respectively and the remaining unamortized cost of the outstanding warrants at March 31, 2016 was $91,036. The aggregate intrinsic value of all of the outstanding and exercisable warrants at March 31, 2016 was $0.

Income Taxes

Income Taxes	12 Months Ended
	Mar. 31, 2016
Income Tax Disclosure [Abstract]
Income Taxes	8. INCOME TAXES The Company has no tax provision for any period presented due to our history of operating losses. As of March 31, 2016, the Company had net operating loss carry forwards of approximately $8,900,000 that may be available to reduce future years’ taxable income through 2030. Future tax benefits which may arise as a result of these losses have not been recognized in these financial statements, as management has determined that their realization is not likely to occur and accordingly, the Company has recorded a valuation allowance for the deferred tax asset relating to these tax loss carry-forwards. The Company adopted accounting rules which address the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under these rules, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. These accounting rules also provide guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. As of March 31, 2016 no liability for unrecognized tax benefits was required to be recorded.

Distribution and License Agreem

Distribution and License Agreements	6 Months Ended	12 Months Ended
	Sep. 30, 2016	Mar. 31, 2016
DISTRIBUTION AND LICENSE AGREEMENTS [Abstract]
Distribution and License Agreements	7. DISTRIBUTION AND LICENSE AGREEMENTS In August 2014, the Company entered into distribution and license agreements with Qualipride International and certain individuals to provide stevia products to the Company. In connection with these agreements, the Company issued 1,400,000 shares of common stock with a total fair value of $420,000 that was being amortized over a three year vesting term (see Note 4). At September 30, 2016, the accumulated amortization for these shares was $395,000. Also in connection with these agreements, the Company issued warrants to purchase 440,000 shares of common stock with a total fair value of $705,880 (See Note 5). At September 30, 2016, the accumulated amortization for these warrants was $649,860. The distribution and license agreements terminated in August 2016 and beginning September 1, 2016, there is no further amortization of fair value being recorded for the common stock or warrants.	9. DISTRIBUTION AND LICENSE AGREEMENTS Related to our legacy stevia business products and technologies, on August 25, 2014, we entered into a distribution agreement where Qualipride International (“Qualipride”) agreed to provide stevia products to the Company at its cost, plus up to 2% for handling costs and up to a 5% sales commission. The Company will account for such costs as such sales are made, or as such other direct costs are incurred. During the year ended March 31, 2016, neither any sales were made nor were other direct costs incurred pursuant to the terms of the distribution agreement. Concurrently, we also entered into a technology license agreement with Qualipride, Mr. Dong Yuejin and Mr. Guo Yuxiao in which we obtained an exclusive license outside China to use Qualipride’s proprietary methods and designs for stevia extraction and purification facilities. The Company will account for the potential costs of such license and obligation once adequate financing has been received to finance facility construction contemplated within the agreement, if such financing occurs. During the year ended March 31, 2016, the Company did not receive any financing pursuant to the terms of the license agreement. Under employment agreements related to the distribution and license agreements, Mr. Dong and Mr. Guo are entitled to receive an aggregate of 240,000 restricted shares of our common stock (see Note 5) and warrants to purchase up to an aggregate of 440,000 shares of our common stock (see Note 7). An aggregate of 40,000 shares of our restricted common stock and warrants to purchase up to an aggregate of 80,000 shares of our common stock vested immediately upon issuance. An aggregate of 100,000 shares of our restricted common stock and warrants to purchase up to an aggregate of 200,000 shares of our common stock have vesting terms ranging from one to three years. An aggregate of 100,000 shares of our restricted common stock will be issued and warrants to purchase up to an aggregate of 160,000 shares of our common stock will vest once we achieve certain financial and operational milestones. The Company will account for the costs of the 100,000 shares of common stock and warrants to purchase up to an aggregate of 160,000 shares of common stock, at the time their issuance becomes probable. During the year ended March 31, 2016, no such milestones were met and as of the year ended March 31, 2016, we owed no compensation pursuant to these employment agreements. The distribution, license and employment agreements are all scheduled to terminate in August 2016, and the Company does not intend to renew or restructure them unless it obtains significant new strategic partnering interest or supply contracts from multinational ingredient or beverage companies related to its stevia products or technologies.

Related Party Transactions and

Related Party Transactions and Lease Obligations	6 Months Ended	12 Months Ended
	Sep. 30, 2016	Mar. 31, 2016
Related Party Transactions [Abstract]
Related Party Transactions and Lease Obligations	6. RELATED PARTY TRANSACTIONS AND LEASE OBLIGATIONS Related party lease obligations On April 23, 2012, the Company entered into a lease agreement (the “Carlson Lease”) with One World Ranches, LLC (“One World Ranches”), which is jointly-owned by Dr. Avtar Dhillon, the Chairman of the Board of Directors of the Company, and his wife, Diljit Bains, pursuant to which the Company has agreed to lease from One World Ranches certain office and laboratory space located at 5225 Carlson Road, Yuba City, California. The Carlson Lease began on May 1, 2012 and expires on May 1, 2017, and the Company’s rent payments thereunder are $2,300 per month. The Company has paid $1,500 as a refundable security deposit under the Carlson Lease. Aggregate payments under the above lease for the six months ended September 30, 2016 and 2015 were $0 and $15,800, respectively.	10. RELATED PARTY TRANSACTIONS AND LEASE OBLIGATIONS Related party lease obligations On April 23, 2012, the Company entered into a lease agreement with One World Ranches LLC (“One World Ranches”), pursuant to which the Company has agreed to lease from One World Ranches certain office and laboratory space located at 5225 Carlson Road, Yuba City, California (the “Carlson Lease”). The Carlson Lease began on May 1, 2012 and expires on May 1, 2017, and the Company’s rent payments thereunder are $2,300 per month. The Company has paid $1,500 as a refundable security deposit under the Carlson Lease. On August 18, 2012, the Company entered into a lease agreement (the “Sacramento Lease”) with Sacramento Valley Real Estate, which is jointly-owned by Dr. Avtar Dhillon, the Chairman of the Board of Directors of the Company, and his wife, Diljit Bains, pursuant to which the Company leases an apartment located at 33-800 Clark Avenue, Yuba City, California. This Company used this apartment as an alternative to renting hotel rooms for management use since several of our managers are not resident in Yuba City. The month to month lease began on August 20, 2012 and was terminated in June 2015. The Company’s rent payment was $1,000 per month. On August 22, 2012, the Company paid $1,000 as a refundable security deposit under the Sacramento lease. Aggregate payments under the above leases for the years ended March 31, 2016 and 2015 were $30,600 and $49,000, respectively.

Commitments

Commitments	12 Months Ended
	Mar. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments	11. COMMITMENTS Related to our legacy stevia products and technologies, in addition to intellectual property developed internally, we previously licensed exclusive and worldwide rights to certain patents and patent applications related to microbial production of steviol and steviol glycosides from Vineland Research and Innovations Centre, Inc. entered into in August 2012, amended in October 2013 (the “Vineland License”), and terminated in May 2016. Pursuant to the Vineland License, we agreed to total cash fees due and payable within the first year of the agreement of $50,000, all of which have been paid and recorded as expenses.Under the Vineland License we will owe royalties of 0.5% of the sale price of products developed using the intellectual property, and in the third year and all subsequent years of the Vineland License the Company will owe a minimum annual royalty of $10,000. No additional payments will be owed under the Vineland License as it was terminated in May 2016.

Subsequent Events

Subsequent Events	6 Months Ended	12 Months Ended
	Sep. 30, 2016	Mar. 31, 2016
Subsequent Events [Abstract]
Subsequent Events	8. SUBSEQUENT EVENT In October 2016, the Company received $204,000 of proceeds from holders of warrants to acquire 1,200,000 shares of common stock.	12. SUBSEQUENT EVENTS In May 2016, the Company entered into a securities purchase agreement with the purchasers identified therein providing for the issuance and sale by the Company to the purchasers, in a private placement, of an aggregate of 2,650,000 shares of the Company’s common stock (collectively, the “Shares”) and Warrants to purchase up to an aggregate of 7,950,000 shares of the Company’s common stock,(the “Warrants”, and the shares issuable upon exercise of the Warrants, collectively, the “Warrant Shares”), at a price of $0.10 per Share (the “Offering”). The Warrants have an exercise price of $0.17 per share and expire six months from the date of issuance. The Offering closed on May 4, 2016. The aggregate proceeds to the Company from the sale of the Shares and Warrants was approximately $265,000. In May 2016, we received shareholder and board approval for a name change to Vitality Biopharma, Inc., an exchange of one (1) share of the Company’s common stock for each 10 shares of common stock outstanding or exercisable under any outstanding warrants or option agreements and an increase in the number of shares of authorized common stock from 525,000,000 to 1,000,000,000. These corporate changes became effective on July 20, 2016 and are reflected in these financial statements. In July 2016, we issued options to purchase 1,525,703 shares of our common stock to six employees and one director with a fair value of $365,330 which will be amortized over 24 months as the options vest. The fair value of these options granted was estimated using the Black-Scholes option pricing model based on the following assumptions: (i) volatility rate of 126.34%, (ii) discount rate of 1.60 %, (iii) zero expected dividend yield, and (iv) expected life of 5 years. These options have an exercise price of $0.50 per share and expire ten years from the date of issuance. In July 2016, we issued options to purchase 185,118 shares of our common stock to two consultants with a fair value of $44,326 at grant date. These options have an exercise price of $0.50 per share and expire ten years from the date of issuance. The fair value of these options granted to the consultants was estimated using the Black-Scholes option pricing model based on the following assumptions: (i) volatility rate of 126.34%, (ii) discount rate of 1.60 %, (iii) zero expected dividend yield, and (iv) expected life of 5 years. The fair value of the option grants to the consultants will be recalculated each quarter and will be amortized over 24 months as the options vest based on their fair value at the end of each quarterly reporting period. In July 2016, we issued 1,436,170 shares of restricted common stock to our Chief Executive Officer and the Chairman of our board of directors with a fair value of $718,015, which will be amortized over 20 months as the shares vest.

Summary of Significant Accoun20

Summary of Significant Accounting Policies (Policies)	6 Months Ended	12 Months Ended
	Sep. 30, 2016	Mar. 31, 2016
Accounting Policies [Abstract]
Going Concern	Going Concern These financial statements have been prepared on a going concern basis which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying financial statements, for the six months ended September 30, 2016, the Company incurred a net loss of $1,585,924 and utilized $578,800 of cash in operations, and at September 30, 21016, had a stockholders’ deficit of $920,452. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. In addition, the Company’s independent registered public accounting firm, in their report on the Company’s March 31, 2016 audited financial statements, raised substantial doubt about the Company’s ability to continue as a going concern. These financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern. The ability to continue as a going concern is dependent on the Company attaining and maintaining profitable operations in the future and/or raising additional capital to meet its obligations and repay its liabilities arising from normal business operations when they come due. We estimate that we will have sufficient funds to operate the Company through December 31, 2016. These estimates could differ if we encounter unanticipated difficulties, in which case our current funds may not be sufficient to operate our business for that period. In addition, our estimates of the amount of cash necessary to operate our business may prove to be wrong, and we could spend our available financial resources much faster than we currently expect. We do not have any firm commitments for future capital. We will need to raise additional funds in order to continue operating our business and pursue and execute our planned research and development and commercial operations. We do not presently have, nor do we expect in the near future to have, sufficient or consistent revenue to fund our business from our operations, and will need to obtain significant funding from external sources. Since inception, we have funded our operations primarily through equity and debt financings, and we expect to continue to rely on these sources of capital in the future. However, if we raise additional funds by issuing equity or convertible debt securities, our existing stockholders’ ownership will be diluted, and obtaining commercial loans would increase our liabilities and future cash commitments. If we pursue capital through alternative sources, such as collaborations or other similar arrangements, we may be forced to relinquish rights to our proprietary technology or other intellectual property that could result in our receipt of only a portion of any revenue that may be generated from a partnered product or business. Further, these or other sources of capital may not be available on commercially reasonable or acceptable terms when needed, or at all. If we cannot raise the money that we need in order to continue to operate and develop our business, we will be forced to delay, scale back or eliminate some or all of our operations. If any of these were to occur, there is a substantial risk that our business would fail and our stockholders could lose all of their investment.
Basis of Presentation of Unaudited Condensed Financial Information	Basis of Presentation of Unaudited Condensed Financial Information The unaudited condensed financial statements of the Company for the six months ended September 30, 2016 and 2015 have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information, applied on a consistent basis, and pursuant to the requirements for reporting on Form 10-Q and the requirements of Regulation S-K and Regulation S-X promulgated under the Securities Act of 1933, as amended (the “Securities Act”). Accordingly, they do not include all the information and footnotes required by U.S. GAAP for complete audited financial statements. However, the information included in these financial statements reflects all adjustments (consisting solely of normal recurring adjustments), which are, in the opinion of management, necessary for the fair presentation of the Company’s financial position and the results of operations. Results shown for interim periods are not necessarily indicative of the results to be obtained for a full fiscal year or any future annual or interim period. The balance sheet information as of March 31, 2016 was derived from the audited financial statements as of and for the year ended March 31, 2016 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on June 24, 2016. These financial statements should be read in conjunction with that report.
Use of Estimates and Assumptions	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. The more significant estimates and assumptions by management include, among others, the fair value of equity instruments issued for services, and assumptions used in the valuation of our outstanding derivative liabilities.	Use of Estimates and Assumptions The preparation of financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. The more significant estimates and assumptions by management include, among others, reserves for accounts receivable, the fair value of equity instruments issued for services, and input assumptions used in the valuation of derivative liabilities.
Revenues	Revenue Recognition Revenue is measured at the fair value of the consideration received or receivable and represents amounts receivable for products and/or services that have been delivered in the normal course of business, title has passed, the selling price is both fixed and determinable, and collectability is reasonably assured, all of which generally occurs upon shipment of the Company’s product or delivery of the product to the destination specified by the customer. The Company determines whether delivery has occurred based on when title transfers and the risks and rewards of ownership have transferred to the buyer, which usually occurs when the Company ships the products. The Company regularly reviews its customers’ financial positions to ensure that collectability is reasonably assured. Except for warranties, the Company has no post-sales obligations.	Revenues Revenue is measured at the fair value of the consideration received or receivable and represents amounts receivable for products and/or services that have been delivered in the normal course of business, title has passed, the selling price is both fixed and determinable, and collectability is reasonably assured, all of which generally occurs upon shipment of the Company’s product or delivery of the product to the destination specified by the customer. The Company determines whether delivery has occurred based on when title transfers and the risks and rewards of ownership have transferred to the buyer, which usually occurs when the Company ships the products. The Company regularly reviews its customers’ financial positions to ensure that collectability is reasonably assured. Except for warranties, the Company has no post-sales obligations.
Accounts Receivable	Accounts Receivable The Company evaluates the collectability of its trade accounts receivable based on a number of factors. In circumstances where the Company becomes aware of a specific customer’s inability to meet its financial obligations to the Company, a specific reserve for bad debts is estimated and recorded, which reduces the recognized receivable to the estimated amount the Company believes will ultimately be collected. In addition to specific customer identification of potential bad debts, bad debt charges are recorded based on the Company’s historical losses and an overall assessment of past due trade accounts receivable outstanding. The allowance for doubtful accounts and returns and discounts is established through a provision reducing the carrying value of receivables. At September 30, 2016, and March 31, 2016, the allowance for doubtful accounts and returns and discounts was approximately $35,500 and $17,517, respectively.	Accounts Receivable The Company evaluates the collectability of its trade accounts receivable based on a number of factors. In circumstances where the Company becomes aware of a specific customer’s inability to meet its financial obligations to the Company, a specific reserve for bad debts is estimated and recorded, which reduces the recognized receivable to the estimated amount the Company believes will ultimately be collected. In addition to specific customer identification of potential bad debts, bad debt charges are recorded based on the Company’s historical losses and an overall assessment of past due trade accounts receivable outstanding. The allowance for doubtful accounts and returns and discounts is established through a provision reducing the carrying value of receivables. At March 31, 2016 and 2015, the allowance for doubtful accounts and returns and discounts was approximately $17,500 and $2,500, respectively.
Financial Assets and Liabilities Measured at Fair Value	Financial Assets and Liabilities Measured at Fair Value The Company accounts for the fair value of financial instruments in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (ASC) topic 820, “Fair Value Measurements and Disclosures” (ASC 820). ASC 820 defines “fair value” as the price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Authoritative guidance provided by the FASB defines the following levels directly related to the amount of subjectivity associated with the inputs to fair valuation of these financial assets: Level 1 Quoted prices in active markets for identical assets or liabilities. Level 2 Inputs, other than quoted prices in active markets, that are observable either directly or indirectly. Level 3 Unobservable inputs based on the Company’s assumptions. The carrying amounts reported in the balance sheets for cash and cash equivalents, accounts payable and accrued liabilities, each qualify as financial instruments and are a reasonable estimate of their fair values because of the short period of time between the origination of such instruments and their expected realization and their current market rate of interest. The Company uses Level 2 inputs for its valuation methodology for the warrant derivative liabilities as their fair values were determined by using a probability weighted average Black-Scholes-Merton pricing model based on various assumptions. The Company’s derivative liabilities are adjusted to reflect fair value at each period end, with any increase or decrease in the fair value being recorded in results of operations as adjustments to fair value of derivatives. At September 30, 2016 and March 31, 2016, the Company’s balance sheet includes the fair value of derivative liabilities of $663,810 and $401,127, respectively, that were measured using level 2 measurements. The Company did not identify any other non-recurring assets and liabilities that are required to be presented in the balance sheets at fair value in accordance with ASC 815.	Financial Assets and Liabilities Measured at Fair Value The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis. Financial assets recorded at fair value in the balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value. Authoritative guidance provided by FASB defines the following levels directly related to the amount of subjectivity associated with the inputs to fair valuation of these financial assets: Level 1 Quoted prices in active markets for identical assets or liabilities. Level 2 Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly. Level 3 Unobservable inputs based on the Company’s assumptions. The fair value of the derivative liabilities of $401,127 and $1,406,596 at March 31, 2016 and 2015, respectively, were valued using Level 2 inputs. The carrying value of cash and accounts payable and accrued liabilities approximates their fair value because of the short maturity of these instruments. Unless otherwise noted, it is management’s opinion that the Company is not exposed to significant interest, currency or credit risks arising from these financial instruments.
Derivative Financial Instruments	Derivative Financial Instruments The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company uses a probability weighted average Black-Scholes-Merton model to value the derivative instruments at inception and on subsequent valuation dates through the September 30, 2016 reporting date. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date.	Derivative Financial Instruments The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company uses a probability weighted average Black-Scholes-Merton models to value the derivative instruments at inception and on subsequent valuation dates through the March 31, 2016, reporting date. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period.
Income Taxes		Income Taxes The Company follows the asset and liability method of accounting for income taxes. Under this method, deferred income tax assets and liabilities are recognized for the estimated tax consequences attributable to differences between the financial statement carrying values and their respective income tax basis (temporary differences). The effect on deferred income tax assets and liabilities of a change in tax rates is recognized as income (loss) in the period that includes the enactment date.
Stock-Based Compensation	Stock-Based Compensation The Company periodically issues stock options and warrants to employees and non-employees in non-capital raising transactions, for services and for financing costs. The Company accounts for share-based payments under the guidance as set forth in the Share-Based Payment Topic of the FASB ASC, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, officers, directors, and consultants, including employee stock options, based on estimated fair values. The Company estimates the fair value of share-based payment awards to employees and directors on the date of grant using an option-pricing model, and the value of the portion of the award that is ultimately expected to vest is recognized as expense over the required service period in the Company’s statements of operations. The Company accounts for stock option and warrant grants issued and vesting to non-employees in accordance with the authoritative guidance whereas the value of the stock compensation is based upon the measurement date as determined at either (a) the date at which a performance commitment is reached, or (b) the date at which the necessary performance to earn the equity instruments is complete. Stock-based compensation is based on awards ultimately expected to vest and is reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, as necessary, in subsequent periods if actual forfeitures differ from those estimates.	Stock-Based Compensation The Company periodically issues stock options and warrants to employees and non-employees in non-capital raising transactions, for services and for financing costs. The Company accounts for share-based payments under the guidance as set forth in the Share-Based Payment Topic of the FASB Accounting Standards Codification (“ASC”), which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, officers, directors, and consultants, including employee stock options, based on estimated fair values. The Company estimates the fair value of share-based payment awards to employees and directors on the date of grant using a Black-Scholes-Merton option-pricing model, and the value of the portion of the award that is ultimately expected to vest is recognized as expense over the required service period in the Company’s statements of operations. The Company accounts for stock option and warrant grants issued and vesting to non-employees in accordance with the authoritative guidance whereas the value of the stock compensation is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) the date at which the necessary performance to earn the equity instruments is complete. Stock-based compensation is based on awards ultimately expected to vest and is reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, as necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company periodically issues unvested (“restricted”) shares of its common stock to employees as equity incentives. The Company’s restricted stock vests upon the satisfaction of a recipient’s service condition, which is satisfied over a period of number of years. The restricted shares vest over certain period and remain subject to forfeiture if vesting conditions are not met. The Company values the shares based on the price per share of the Company’s shares at the date of grant and recognizes the value as compensation expense ratably over the vesting period.
Basic and Diluted Loss Per Share	Basic and Diluted Loss Per Share The Company’s computation of earnings (loss) per share (EPS) includes basic and diluted EPS. Basic EPS is calculated by dividing the Company’s net income (loss) available to common stockholders by the weighted average number of common shares during the period. Shares of restricted stock subject to vesting are included in basic weighted average common shares outstanding from the time they vest. Diluted EPS reflects the potential dilution, using the treasury stock method that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the net income (loss) of the Company. In computing diluted EPS, the treasury stock method assumes that outstanding options and warrants are exercised and the proceeds are used to purchase common stock at the average market price during the period. As of September 30, 2016 potentially dilutive securities include options to acquire 2,652,488 shares of common stock and warrants to acquire 9,702,713 shares of common stock. At September 30, 2015 potentially dilutive securities include options to acquire 899,167 shares of common stock and warrants to acquire 2,502,713 shares of common stock. The basic and fully diluted shares for the three and six months ended September 30, 2016 are the same because the inclusion of the potential shares would have had an anti-dilutive effect. Diluted net income per common share for the three and six months ended September 30, 2015 was the same as the exercise price of the potentially dilutive securities was greater than the trading price during the period.	Basic and Diluted Loss Per Share The Company computes loss per share in accordance with ASC Topic 260, “Earnings per Share” which requires presentation of both basic and diluted earnings per share on the face of the statement of operations. Basic loss per share is computed by dividing the net loss applicable to common stockholders by the weighted average number of outstanding common shares during the period. Diluted loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued. Diluted loss per share excludes all potential common shares if their effect is anti-dilutive. The following potentially dilutive shares were excluded from the shares used to calculate diluted earnings per share as their inclusion would be anti-dilutive: March 31, 2016 2015 Options 909,167 632,500 Warrants 2,002,713 1,212,713 Total 2,911,880 1,845,213
Research and Development		Research and Development Research and development costs consist primarily of fees paid to consultants and outside service providers, patent fees and costs, and other expenses relating to the acquisition, design, development and testing of the Company’s treatments and product candidates. Research and development costs are expensed as incurred over the life of the underlying contracts on the straight-line basis, unless the achievement of milestones, the completion of contracted work, or other information indicates that a different expensing schedule is more appropriate. The Company reviews the status of its research and development contracts on a quarterly basis.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers In August 2014, the FASB issued Accounting Standards Update No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern In February 2016, the FASB issued Accounting Standards Update (ASU) No. 2016-02, Leases In March 2016, the FASB issued the ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The amendments in this ASU require, among other things, that all income tax effects of awards be recognized in the income statement when the awards vest or are settled. The ASU also allows for an employer to repurchase more of an employee's shares than it can today for tax withholding purposes without triggering liability accounting and allows for a policy election to account for forfeitures as they occur. The amendments in this ASU are effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted for any entity in any interim or annual period. The Company is currently evaluating the expected impact that the standard could have on its financial statements and related disclosures. Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.	Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers In August 2014, the FASB issued Accounting Standards Update No. 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern In November 2014, the FASB issued Accounting Standards Update No. 2014-16, Determining Whether the Host Contract in a Hybrid Financial Instrument Issued in the Form of a Share Is More Akin to Debt or to Equity. The amendments in ASU 2014-6 do not change the current criteria in U.S. GAAP for determining when separation of certain embedded derivative features in a hybrid financial instrument is required. The amendments clarify that an entity should consider all relevant terms and features, including the embedded derivative feature being evaluated for bifurcation, in evaluating the nature of the host contract. ASU 2014-6 applies to all entities that are issuers of, or investors in, hybrid financial instruments that are issued in the form of a share and is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. Early adoption is permitted. The Company is currently evaluating the expected impact that the standard could have on its financial statements and related disclosures. In February 2016, the FASB issued Accounting Standards Update (ASU) No. 2016-02, Leases Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

Summary of Significant Accoun21

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Antidilutive Securities Excluded from Computation of Earnings Per Share	The following potentially dilutive shares were excluded from the shares used to calculate diluted earnings per share as their inclusion would be anti-dilutive: March 31, 2016 2015 Options 909,167 632,500 Warrants 2,002,713 1,212,713 Total 2,911,880 1,845,213

Derivative Liability (Tables)

Derivative Liability (Tables)	6 Months Ended	12 Months Ended
	Sep. 30, 2016	Mar. 31, 2016
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Valuation Assumptions for Derivative Liabilities	As of March 31, 2016 and September 30, 2016, the derivative liabilities were valued using a probability weighted average Black-Scholes-Merton pricing model with the following assumptions: Warrants: September 30, 2016 March 31, 2016 Exercise Price $ 2.00 - 4.25 $ 3.00 - 4.50 Stock Price $ 1.08 $ 0.70 Risk-free interest rate 0.59 - 0.98 % 0.19 - 1.04 % Expected volatility 127.45 % 105.06 - 124.77 % Expected life (in years) 1.0 - 3.7 years 0.1 - 4.2 years Expected dividend yield 0 0 Fair Value: $ 663,810 $ 401,127	At the applicable dates of issuance and as of March 31, 2015 and March 31, 2016, the derivative liabilities were valued using a probability weighted average Black-Scholes-Merton pricing model with the following assumptions: Date of Modification September 24, 2014 March 31, 2015 Upon Issuance May 11, 2015 March 31, 2016 Exercise Price $ 4.00 – 4.50 $ 3.40 - 4.50 $ 3.50 - 4.50 $ 3.00 – 4.50 Stock Price $ 4.20 $ 3.80 $ 2.90 $ 0.70 Risk-free interest rate 1.78 - 2.0 % 0.41 - 1.25 % 0.17 - 1.59 % 0.19 – 1.04 % Expected volatility 84.45 % 76.26 % 76.26 - 107.5 % 105.06 - 124.77 % Expected life (in years) 0.01 – 5.0 years 2.50 - 4.5 years 0.75 – 5.0 years 0.1 – 4.2 years Expected dividend yield 0.00 0.00 0.00 0.00 Fair Value: $ 961,767 $ 1,406,596 $ 1,694,651 $ 401,127

Stockholders' Equity Deficien23

Stockholders' Equity Deficiency (Tables)	6 Months Ended
	Sep. 30, 2016
Stockholders' Equity Note [Abstract]
Schedule of Nonvested Restricted Stock Unit Activity	The following table summarizes restricted common stock activity: Number of Shares Non-vested shares, March 31, 2016 175,833 Granted 1,436,170 Vested (2,500 ) Forfeited (2,500 ) Non-vested shares, September 30, 2016 1,607,003

Stock Options (Tables)

Stock Options (Tables)	6 Months Ended	12 Months Ended
	Sep. 30, 2016	Mar. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of Stock Option Activity	A summary of the Company’s stock option activity for the six months ended September 30, 2016 is presented below: Shares Weighted Average Exercise Price Balance at March 31, 2016 907,500 $ 3.30 Granted 1,760,821 0.51 Exercised - - Expired (225,000 ) 3.73 Cancelled (15,833 ) 3.40 Balance outstanding at September 30, 2016 2,427,488 $ 1.08 Balance exercisable at September 30,2016 524,167 $ 2.64	A summary of the Company’s stock option activity during the fiscal years ended March 31, 2015 and 2016 is as follows: Shares Weighted Average Exercise Price Balance at March 31, 2014 515,000 $ 2.60 Granted 135,000 Exercised (5,000 ) Cancelled (12,500 ) Balance outstanding at March 31, 2015 632,500 $ 3.30 Granted 275,000 Exercised - Cancelled - Balance outstanding at March 31, 2016 907,500 $ 3.30 Balance exercisable at March 31,2016 679,376 $ 3.20
Options to Purchase Common Shares	At September 30, 2016, options to purchase common shares were outstanding as follows: Number of options Weighted Average Exercise Price Weighted Average Grant-date Stock Price Options Outstanding, September 30, 2016 1,710,821 $ 0.50 $ 0.5 50,000 $ 0.96 $ 0.96 130,000 $ 1.00 $ 10.00 10,000 $ 1.50 $ 0.40 287,500 $ 2.00 - 2.70 $ 2.00 - 2.70 130,000 $ 3.10 - 3.80 $ 3.10 - 3.80 49,167 $ 4.00 - 4.70 $ 4.00 - 4.70 60,000 $ 5.10 $ 5.10 2,427,488 Options Exercisable, September 30,2016 130,000 $ 1.00 $ 10.00 2,500 $ 1.50 $ 0.40 177,500 $ 2.00 - 2.70 $ 2.00 - 2.70 108,334 $ 3.10 - 3.80 $ 3.10 - 3.80 45,833 $ 4.00 - 4.70 $ 4.00 - 4.70 60,000 $ 5.10 $ 5.10 524,167	A summary of the Company’s stock options outstanding as of March 31, 2016 is as follows: Number of Options Weighted Average Exercise Price Weighted Average Grant-date Stock Price Options Outstanding, March 31, 2016 130,000 $ 1.00 $ 10.00 10,000 1.50 1.50 287,500 $ 2.00 - 2.70 $ 2.00 - 2.70 220,000 $ 3.10 - 3.80 $ 3.10 - 3.80 199,167 $ 4.00 - 4.70 $ 4.00 - 4.70 60,000 $ 5.10 $ 5.10 907,500 Options Exercisable, March 31, 2016 130,000 $ 1.00 $ 10.00 123,750 $ 2.00 - 2.70 $ 2.00 - 2.70 171,667 $ 3.10 - 3.80 $ 3.10 - 3.80 193,959 $ 4.00 - 4.70 $ 4.00 - 4.70 60,000 $ 5.10 $ 5.10 679,376

Warrants (Tables)

Warrants (Tables)	6 Months Ended	12 Months Ended
	Sep. 30, 2016	Mar. 31, 2016
Warrants and Rights Note Disclosure [Abstract]
Summary of Warrant Activity	At September 30, 2016, warrants to purchase common shares were outstanding as follows: Shares Weighted Average Exercise Price Balance at March 31, 2016 2,002,718 $ 3.50 Granted 7,950,000 0.17 Exercised (2,070,590 ) 0.17 Expired (250,000 ) $ 4.00 Balance outstanding and exercisable at September 30, 2016 7,632,128 $ 0.65	A summary of warrants to purchase common stock issued during the fiscal years ended March 31, 2015 and 2016 is as follows: Shares Weighted Average Exercise Price Balance outstanding at March 31, 2014 772,717 $ 4.10 Granted 807,648 3.70 Exercised (367,647 ) 4.00 Cancelled - - Balance outstanding at March 31, 2015 1,212,718 $ 3.90 Granted 1,290,000 3.40 Exercised - - Expired (500,000 ) 3.50 Balance outstanding at March 31, 2016 2,002,718 $ 3.50 Balance exercisable at March 31, 2016 2,002,718 $ 3.50

Business and Basis of Operati26

Business and Basis of Operations (Details Narrative)	Oct. 11, 2011$ / sharesshares	Mar. 31, 2016USD ($)$ / sharesshares	Sep. 30, 2016USD ($)$ / sharesshares	Mar. 31, 2016USD ($)$ / sharesshares	May 31, 2016shares	Mar. 31, 2015USD ($)$ / sharesshares	Mar. 31, 2014USD ($)	Oct. 09, 2011$ / sharesshares
Stock split description			Reverse split of our outstanding common shares whereby each 10 shares of common stock will be exchanged for 1 share of common stock	In May 2016, we received shareholder and board approval for a name change to Vitality Biopharma, Inc., an exchange of one (1) share of the Company's common stock for each 10 shares of common stock outstanding or exercisable under any outstanding warrants or option agreements
Common stock, shares authorized	525,000,000	1,000,000,000	1,000,000,000	1,000,000,000		1,000,000,000		75,000,000
Common stock, par value | $ / shares	$ 0.001	$ 0.001	$ 0.001	$ 0.001		$ 0.001		$ 0.001
Common stock, shares issued	51,450,000	7,911,708	14,380,968	7,911,708		7,296,892		7,350,000
Common stock, shares outstanding	51,450,000	7,911,708	14,380,968	7,911,708		7,296,892		7,350,000
Stockholders' equity (deficiency) | $		$ (518,165)	$ (920,452)	$ (518,165)		$ (1,079,300)	$ (110,376)
Proceeds from issuance of private placement | $		$ 99,970		$ 265,000
Minimum [Member]
Common stock, shares authorized			525,000,000		525,000,000
Maximum [Member]
Common stock, shares authorized			1,000,000,000		1,000,000,000
May 2016 [Member]
Stock split, conversion ratio				10
Common Stock [Member]
Stock split description				on October 10, 2011, we effected a seven for one forward stock split of authorized, issued and outstanding common stock. As a result, our authorized capital was increased from 75,000,000 shares of common stock with a par value of $0.001 to 525,000,000 shares of common stock with a par value of $0.001, and issued and outstanding shares increased from 7,350,000 to 51,450,000.
Stock split, conversion ratio	7

Business and Summary of Signifi

Business and Summary of Significant Accounting Policies (Details Narrative) (10Q) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Mar. 31, 2016	Mar. 31, 2015	May 31, 2016	Mar. 31, 2014	Oct. 11, 2011	Oct. 09, 2011
Stock split description			Reverse split of our outstanding common shares whereby each 10 shares of common stock will be exchanged for 1 share of common stock		In May 2016, we received shareholder and board approval for a name change to Vitality Biopharma, Inc., an exchange of one (1) share of the Company's common stock for each 10 shares of common stock outstanding or exercisable under any outstanding warrants or option agreements
Common stock, shares authorized	1,000,000,000		1,000,000,000		1,000,000,000	1,000,000,000			525,000,000	75,000,000
Net loss	$ 1,146,519	$ (504,326)	$ 1,585,924	$ (719,920)	$ 141,325	$ 4,048,373
Net cash used in operating activities			578,800	$ 988,625	1,685,841	2,499,766
Stockholders' deficiency	920,452		920,452		518,165	1,079,300		$ 110,376
Allowance for doubtful accounts receivable	35,500		35,500		17,517	$ 2,500
Fair value of derivative liabilities	$ 663,810		$ 663,810		$ 401,127
Antidilutive securities excluded from computation of earnings per share					2,911,880	1,845,213
Stock Option [Member]
Antidilutive securities excluded from computation of earnings per share			2,652,488	899,167
Warrant [Member]
Antidilutive securities excluded from computation of earnings per share			9,702,713	2,502,713	2,002,713	1,212,713
Minimum [Member]
Common stock, shares authorized	525,000,000		525,000,000				525,000,000
Maximum [Member]
Common stock, shares authorized	1,000,000,000		1,000,000,000				1,000,000,000

Summary of Significant Accoun28

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	Sep. 30, 2016	Mar. 31, 2016	May 11, 2015	Mar. 31, 2015	Sep. 24, 2014
Accounting Policies [Abstract]
Allowance for doubtful accounts receivable	$ 35,500	$ 17,517		$ 2,500
Derivative liability	$ 663,810	$ 401,127	$ 1,694,651	$ 1,406,596	$ 961,767

Summary of Significant Accoun29

Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Earnings per Share (Details) - shares	6 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Mar. 31, 2016	Mar. 31, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share			2,911,880	1,845,213
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share			909,167	632,500
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share	9,702,713	2,502,713	2,002,713	1,212,713

Acquisition From Related Party

Acquisition From Related Party (Details Narrative) - USD ($)	May 16, 2014	Mar. 31, 2016	Sep. 30, 2016	Mar. 31, 2015
Accounts payable and accrued liabilities		$ 244,937	$ 307,070	$ 134,007
Percipio Biosciences Inc [Member]
Purchase of assets from related party	$ 50,000
Accounts payable and accrued liabilities		11,950
Senior scientist annual salary		$ 95,000
Percipio Biosciences Inc [Member] | Chief Executive Officer [Member]
Ownership percentage in acquired party held by an officer of the reporting entity	20.00%

Derivative Liability (Details N

Derivative Liability (Details Narrative) - USD ($)	Sep. 10, 2014	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Mar. 31, 2016	Mar. 31, 2015	May 11, 2015	Sep. 24, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Warrants valuation method				Black-Scholes-Merton pricing model		Black-Scholes-Merton pricing model
Cost to induce exercise of warrants	$ 21,218						$ (961,767)
Fair value of warrants accounted for as derivatives	$ 940,549
Extinguishment of derivative liability				$ 80,278		99,311	269,368
Change in fair value of derivative liability		$ (328,008)	$ 1,198,954	(342,961)	$ 2,312,755	2,600,809	724,617
Derivative liability		$ 663,810		$ 663,810		$ 401,127	$ 1,406,596	$ 1,694,651	$ 961,767

Derivative Liability (Details32

Derivative Liability (Details Narrative) (10Q) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Mar. 31, 2016	Mar. 31, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Warrants valuation method			Black-Scholes-Merton pricing model		Black-Scholes-Merton pricing model
Derivative expiry date					May 31, 2016
Change in fair value of derivative liability	$ 328,008	$ (1,198,954)	$ 342,961	$ (2,312,755)	$ (2,600,809)	$ (724,617)
Fair value of derivative liabilities	$ 663,810		663,810		$ 401,127
Extinguishment of derivative liability			$ 80,278

Derivative Liability - Valuatio

Derivative Liability - Valuation Assumptions for Derivative Liabilities (Details) - USD ($)	May 11, 2015	Sep. 24, 2014	Sep. 30, 2016	Mar. 31, 2016	Mar. 31, 2015
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Stock Price	$ 2.90	$ 4.20	$ 1.08	$ 0.70	$ 3.80
Expected volatility		84.45%	127.45%		76.26%
Expected dividend yield	0.00%	0.00%	0.00%	0.00%	0.00%
Fair Value of Derivative Liability	$ 1,694,651	$ 961,767	$ 663,810	$ 401,127	$ 1,406,596
Minimum [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Exercise Price	$ 3.50	$ 4	$ 2	$ 3	$ 3.40
Risk-free interest rate	0.17%	1.78%	0.59%	0.19%	0.41%
Expected volatility	76.26%			105.06%
Expected life (in years)	9 months	4 days	1 year	1 month 6 days	2 years 6 months
Maximum [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Exercise Price	$ 4.50	$ 4.50	$ 4.25	$ 4.50	$ 4.50
Risk-free interest rate	1.59%	2.00%	0.98%	1.04%	1.25%
Expected volatility	107.50%			124.77%
Expected life (in years)	5 years	5 years	3 years 8 months 12 days	4 years 2 months 12 days	4 years 6 months

Stockholders' Equity Deficien34

Stockholders' Equity Deficiency - Equity Financing (Details Narrative) - USD ($)	1 Months Ended		6 Months Ended		12 Months Ended
	May 31, 2016	May 31, 2015	Sep. 30, 2016	Sep. 30, 2015	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from sale of common stock and warrants, net	$ 165,030		$ 165,030	$ 1,291,574	$ 1,291,574
Exercise price of warrants			$ 0.65		$ 3.50	$ 3.90	$ 4.10
Value of warrants issued, derivative liability		$ 1,694,651
Adjustments to additional paid in capital, warrants issued			$ 35,014		$ 182,072	$ 432,772
Shares issued, value	$ 99,970		$ 165,030		$ (403,077)
Securities Purchase Agreement Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued as part of private placement	2,650,000	500,000
Number of shares called by exercise of warrants	7,950,000	1,250,001
Proceeds from sale of common stock and warrants, gross		$ 1,500,000
Shares issued, price per share	$ 0.10	$ 3
Payments of stock issuance costs		$ 208,426
Proceeds from sale of common stock and warrants, net	$ 265,000	1,291,574
Exercise price of warrants	$ 0.17
Value of warrants issued, derivative liability		1,694,651
Adjustments to additional paid in capital, warrants issued		$ 408,077
Securities Purchase Agreement Warrants Series One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares called by exercise of warrants		500,000
Exercise price of warrants		$ 4.50
Exercise term of warrants issued		5 years
Minumum exercise price for automatic reset provision					$ 2
Securities Purchase Agreement Warrants Series Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares called by exercise of warrants		500,000
Exercise price of warrants		$ 3.50
Exercise term of warrants issued		9 months
Securities Purchase Agreement Warrants Series Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares called by exercise of warrants		250,000
Exercise price of warrants		$ 4
Exercise term of warrants issued		1 year
Placement Agent Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares called by exercise of warrants		40,000
Exercise price of warrants		$ 3.75
Exercise term of warrants issued		5 years
Minumum exercise price for automatic reset provision		$ 2

Stockholders' Equity Deficien35

Stockholders' Equity Deficiency - Common Stock Issued to Employees for Services with Vesting Terms (Details Narrative) - USD ($)	1 Months Ended			2 Months Ended	6 Months Ended		12 Months Ended
	Aug. 31, 2014	May 31, 2014	Jul. 31, 2013	Aug. 31, 2012	Sep. 30, 2016	Sep. 30, 2015	Mar. 31, 2016	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued to employees	140,000
Fair value of shares issued to employees	$ 420,000						$ 683,000
Vesting period of shares granted					1 year 4 months 24 days
Shares vested					$ 129,749	$ 59,234	161,936	$ 329,511
Stock-based compensation expense not yet recognized					$ 614,000		$ 86,000
Reclassication of unvested, issued common stock to paid-in capital
Vesting Immediately [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued to employees								40,000
Vesting12 To36 Months [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued to employees								100,000
Minimum [Member] | Vesting12 To36 Months [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period of shares granted								12 months
Maximum [Member] | Vesting12 To36 Months [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period of shares granted								36 months
Twenty Twelve Stock Incentive Plan [Member] | Vesting 16 To 60 Months [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued to employees				70,000
Fair value of shares issued to employees				$ 189,000
Twenty Twelve Stock Incentive Plan [Member] | Vesting 31 Months [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued to employees			10,000
Fair value of shares issued to employees			$ 36,000
Vesting period of shares granted			31 months
Twenty Twelve Stock Incentive Plan [Member] | Vesting 24 Months [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued to employees		10,000
Fair value of shares issued to employees		$ 38,000
Vesting period of shares granted		24 months
Twenty Twelve Stock Incentive Plan [Member] | Minimum [Member] | Vesting 16 To 60 Months [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period of shares granted				16 months
Twenty Twelve Stock Incentive Plan [Member] | Maximum [Member] | Vesting 16 To 60 Months [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period of shares granted				60 months
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued to employees							100,000
Unvested Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Reclassication of unvested, issued common stock to paid-in capital							$ 149,714

Stockholders' Equity Deficien36

Stockholders' Equity Deficiency - Common Stock Issued to Consultants for Services (Details Narrative) - USD ($)	1 Months Ended				2 Months Ended	6 Months Ended	12 Months Ended
	Jul. 31, 2015	May 31, 2015	Mar. 31, 2015	Dec. 31, 2014	Nov. 30, 2015	Sep. 30, 2016	Mar. 31, 2016	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock issued for services, shares	31,000	32,500			51,316
Common stock issued for services, value	$ 61,000	$ 115,000			$ 100,000	$ 221,250	$ 276,000	$ 338,900
Twenty Twelve Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock issued for services, shares			4,000	7,895
Common stock issued for services, value			$ 14,800	$ 30,000
Employment Contracts [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock issued for services, shares								79,098
Common stock issued for services, value								$ 294,100

Equity (Details Narrative) (10Q

Equity (Details Narrative) (10Q) - USD ($)	1 Months Ended			6 Months Ended		12 Months Ended
	May 31, 2016	May 31, 2015	Aug. 31, 2014	Sep. 30, 2016	Sep. 30, 2015	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Proceeds from sale of common stock and warrants, net	$ 165,030			$ 165,030	$ 1,291,574	$ 1,291,574
Exercise price of warrants				$ 0.65		$ 3.50	$ 3.90	$ 4.10
Shares issued, value	$ 99,970			$ 165,030		$ (403,077)
Fair value of shares issued			$ 420,000			683,000
Accumulated vested balance of stock				740,965		611,216
Shares vested				129,749	$ 59,234	161,936	$ 329,511
Stock-based compensation expense not yet recognized				$ 614,000		$ 86,000
Vesting period of shares granted				1 year 4 months 24 days
Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued as part of private placement				1,436,170
Fair value of shares issued				$ 718,000
Director [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued as part of private placement				1,436,170
Fair value of shares issued				$ 718,000
Securities Purchase Agreement Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued as part of private placement	2,650,000	500,000
Number of shares called by exercise of warrants	7,950,000	1,250,001
Shares issued, price per share	$ 0.10	$ 3
Proceeds from sale of common stock and warrants, net	$ 265,000	$ 1,291,574
Exercise price of warrants	$ 0.17
Warrant expire date	Feb. 4, 2017

Equity - Schedule of Nonvested

Equity - Schedule of Nonvested Restricted Stock Unit Activity (Details) (10Q)	6 Months Ended
	Sep. 30, 2016shares
Stockholders' Equity Note [Abstract]
Non-vested shares, Beginning Balance	175,833
Granted	1,436,170
Vested	(2,500)
Forfeited	(2,500)
Non-vested shares, Ending Balance	1,607,003

Stock Options (Details Narrativ

Stock Options (Details Narrative) - USD ($)	1 Months Ended	6 Months Ended		12 Months Ended
	Apr. 30, 2014	Sep. 30, 2016	Sep. 30, 2015	Mar. 31, 2016	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period of shares granted		1 year 4 months 24 days
Options exercised during period					5,000
Options exercised during period, exercise price
Proceeds from exercise of options					$ 5,000
Stock-based compensation, options vested		$ 200,315	$ 149,556	286,248	$ 233,310
Unamortized cost of outstanding stock-based awards		$ 1,045,044		$ 345,000
Weighted average remaining vesting period		2 years		2 years
Options outstanding, intrinsic value		$ 1,000,000	$ 0	$ 0
Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted during period				137,500	112,500
Expiration period of options granted				10 years	10 years
Expected volatility rate of options granted				76.26%	81.84%
Expected discount rate of options granted				2.19%	1.62%
Expected dividend yield of options granted				0.00%	0.00%
Expected life of options granted				5 years	5 years
Grant-date fair value of options granted				$ 233,000	$ 300,000
Consultants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted during period				140,000	22,500
Expected volatility rate of options granted					76.26%
Expected discount rate of options granted				2.17%	2.17%
Expected dividend yield of options granted				0.00%	0.00%
Expected life of options granted				5 years	5 years
Grant-date fair value of options granted				$ 131,000	$ 88,000
Expected volatility rate of options granted, minimum				76.26%
Expected volatility rate of options granted, maximum				107.51%
Options exercised during period	5,000
Options exercised during period, exercise price	$ 1
Proceeds from exercise of options	$ 5,000
Minimum [Member] | Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period of shares granted				0 months	0 months
Minimum [Member] | Consultants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period of options granted				3 years	5 years
Vesting period of shares granted				0 months	0 months
Maximum [Member] | Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period of shares granted				36 months	36 months
Maximum [Member] | Consultants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period of options granted				10 years	10 years
Vesting period of shares granted				36 months	36 months

Stock Options (Details Narrat40

Stock Options (Details Narrative) (10Q) - USD ($)	6 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Mar. 31, 2016	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of option issued to purchase common stock	1,760,821		275,000	135,000
Weighted Average Exercise Price, Granted	$ 0.51
Vesting period of shares granted	1 year 4 months 24 days
Options outstanding, intrinsic value	$ 1,000,000	$ 0	$ 0
Stock-based compensation, options vested	200,315	$ 149,556	286,248	$ 233,310
Unamortized cost of outstanding stock-based awards	$ 1,045,044		$ 345,000
Weighted average remaining vesting period	2 years		2 years
Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of option issued to purchase common stock	1,618,262
Weighted Average Exercise Price, Granted	$ 0.50
Option expiration years	10 years
Vesting period of shares granted	24 months
Option, volatility rate	126.34%
Option, discount rate	1.60%
Option, expected divident rate	0.00%
Option, expected term	6 years
Options outstanding, intrinsic value	$ 775,000
One Consultants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of option issued to purchase common stock	142,559
Weighted Average Exercise Price, Granted	$ 0.50
Option expiration years	10 years
Vesting period of shares granted	24 months
Option, volatility rate	126.34%
Option, discount rate	1.36%
Option, expected divident rate	0.00%
Option, expected term	10 years
Options outstanding, intrinsic value	$ 146,000
Two Consultants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of option issued to purchase common stock	142,559
Weighted Average Exercise Price, Granted	$ 0.96
Option expiration years	10 years
Vesting period of shares granted	24 months
Option, volatility rate	126.34%
Option, discount rate	1.36%
Option, expected divident rate	0.00%
Option, expected term	10 years
Options outstanding, intrinsic value	$ 146,000

Stock Options - Summary of Stoc

Stock Options - Summary of Stock Option Activity (Details) - $ / shares	6 Months Ended	12 Months Ended
	Sep. 30, 2016	Mar. 31, 2016	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Shares, beginning balance outstanding	907,500	632,500	515,000
Shares, Granted	1,760,821	275,000	135,000
Shares, Exercised			(5,000)
Shares, Expired	(225,000)
Shares, Cancelled	(15,833)		(12,500)
Shares, ending balance outstanding	2,427,488	907,500	632,500
Shares, Balance exercisable	524,167	679,376
Weighted Average Exercise Price, beginning balance outstanding	$ 3.30	$ 3.30	$ 2.60
Weighted Average Exercise Price, Granted	0.51
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Expired	3.73
Weighted Average Exercise Price, Cancelled	3.40
Weighted Average Exercise Price, ending balance outstanding	1.08	3.30	$ 3.30
Weighted Average Exercise Price, Balance exercisable	$ 2.64	$ 3.20

Stock Options - Options to Purc

Stock Options - Options to Purchase Common Shares (Details) - $ / shares	6 Months Ended	12 Months Ended
	Sep. 30, 2016	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding	2,427,488	907,500	632,500	515,000
Weighted average exercise price, options outstanding	$ 1.08	$ 3.30	$ 3.30	$ 2.60
Weighted average grant-date stock price, options outstanding	$ 0.51
Number of options exercisable	524,167	679,376
Weighted average exercise price, options exercisable	$ 2.64	$ 3.20
Stock Options One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding	1,710,821	130,000
Weighted average exercise price, options outstanding	$ 0.50	$ 1
Weighted average grant-date stock price, options outstanding	$ 0.5	$ 10
Number of options exercisable	130,000	130,000
Weighted average exercise price, options exercisable	$ 1	$ 1
Weighted average grant-date stock price, options exercisable	$ 10	$ 10
Stock Options Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding	50,000	10,000
Weighted average exercise price, options outstanding	$ 0.96	$ 1.50
Weighted average grant-date stock price, options outstanding	$ 0.96	$ 1.50
Number of options exercisable	2,500	123,750
Weighted average exercise price, options exercisable	$ 1.50
Weighted average grant-date stock price, options exercisable	$ 0.40
Stock Options Two [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average exercise price, options exercisable		$ 2
Weighted average grant-date stock price, options exercisable		2
Stock Options Two [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average exercise price, options exercisable		2.70
Weighted average grant-date stock price, options exercisable		$ 2.70
Stock Options Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding	130,000	287,500
Weighted average exercise price, options outstanding	$ 1
Weighted average grant-date stock price, options outstanding	$ 10
Number of options exercisable	177,500	171,667
Stock Options Three [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average exercise price, options outstanding		$ 2
Weighted average grant-date stock price, options outstanding		2
Weighted average exercise price, options exercisable	$ 2	3.10
Weighted average grant-date stock price, options exercisable	2	3.10
Stock Options Three [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average exercise price, options outstanding		2.70
Weighted average grant-date stock price, options outstanding		2.70
Weighted average exercise price, options exercisable	2.70	3.80
Weighted average grant-date stock price, options exercisable	$ 2.70	$ 3.80
Stock Options Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding	10,000	220,000
Weighted average exercise price, options outstanding	$ 1.50
Weighted average grant-date stock price, options outstanding	$ 0.40
Number of options exercisable	108,334	193,959
Stock Options Four [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average exercise price, options outstanding		$ 3.10
Weighted average grant-date stock price, options outstanding		3.10
Weighted average exercise price, options exercisable	$ 3.10	4
Weighted average grant-date stock price, options exercisable	3.10	4
Stock Options Four [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average exercise price, options outstanding		3.80
Weighted average grant-date stock price, options outstanding		3.80
Weighted average exercise price, options exercisable	3.80	4.70
Weighted average grant-date stock price, options exercisable	$ 3.80	$ 4.70
Stock Options Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding	287,500	199,167
Number of options exercisable	45,833	60,000
Weighted average exercise price, options exercisable		$ 5.10
Weighted average grant-date stock price, options exercisable		5.10
Stock Options Five [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average exercise price, options outstanding	$ 2	4
Weighted average grant-date stock price, options outstanding	2	4
Weighted average exercise price, options exercisable	4
Weighted average grant-date stock price, options exercisable	4
Stock Options Five [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average exercise price, options outstanding	2.70	4.70
Weighted average grant-date stock price, options outstanding	2.70	$ 4.70
Weighted average exercise price, options exercisable	4.70
Weighted average grant-date stock price, options exercisable	$ 4.70
Stock Options Six [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding	130,000	60,000
Weighted average exercise price, options outstanding		$ 5.10
Weighted average grant-date stock price, options outstanding		$ 5.10
Number of options exercisable	60,000
Weighted average exercise price, options exercisable	$ 5.10
Weighted average grant-date stock price, options exercisable	5.10
Stock Options Six [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average exercise price, options outstanding	3.10
Weighted average grant-date stock price, options outstanding	3.10
Stock Options Six [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average exercise price, options outstanding	3.80
Weighted average grant-date stock price, options outstanding	$ 3.80

Stock Options - Options to Pu43

Stock Options - Options to Purchase Common Shares (Details) (10Q) - $ / shares	6 Months Ended	12 Months Ended
	Sep. 30, 2016	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding	2,427,488	907,500	632,500	515,000
Weighted average exercise price, options outstanding	$ 1.08	$ 3.30	$ 3.30	$ 2.60
Weighted average grant-date stock price, options outstanding	$ 0.51
Number of options exercisable	524,167	679,376
Weighted average exercise price, options exercisable	$ 2.64	$ 3.20
Stock Options One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding	1,710,821	130,000
Weighted average exercise price, options outstanding	$ 0.50	$ 1
Weighted average grant-date stock price, options outstanding	$ 0.5	$ 10
Number of options exercisable	130,000	130,000
Weighted average exercise price, options exercisable	$ 1	$ 1
Weighted average grant-date stock price, options exercisable	$ 10	$ 10
Stock Options Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding	50,000	10,000
Weighted average exercise price, options outstanding	$ 0.96	$ 1.50
Weighted average grant-date stock price, options outstanding	$ 0.96	$ 1.50
Number of options exercisable	2,500	123,750
Weighted average exercise price, options exercisable	$ 1.50
Weighted average grant-date stock price, options exercisable	$ 0.40
Stock Options Two [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average exercise price, options exercisable		$ 2
Weighted average grant-date stock price, options exercisable		2
Stock Options Two [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average exercise price, options exercisable		2.70
Weighted average grant-date stock price, options exercisable		$ 2.70
Stock Options Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding	130,000	287,500
Weighted average exercise price, options outstanding	$ 1
Weighted average grant-date stock price, options outstanding	$ 10
Number of options exercisable	177,500	171,667
Stock Options Three [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average exercise price, options outstanding		$ 2
Weighted average grant-date stock price, options outstanding		2
Weighted average exercise price, options exercisable	$ 2	3.10
Weighted average grant-date stock price, options exercisable	2	3.10
Stock Options Three [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average exercise price, options outstanding		2.70
Weighted average grant-date stock price, options outstanding		2.70
Weighted average exercise price, options exercisable	2.70	3.80
Weighted average grant-date stock price, options exercisable	$ 2.70	$ 3.80
Stock Options Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding	10,000	220,000
Weighted average exercise price, options outstanding	$ 1.50
Weighted average grant-date stock price, options outstanding	$ 0.40
Number of options exercisable	108,334	193,959
Stock Options Four [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average exercise price, options outstanding		$ 3.10
Weighted average grant-date stock price, options outstanding		3.10
Weighted average exercise price, options exercisable	$ 3.10	4
Weighted average grant-date stock price, options exercisable	3.10	4
Stock Options Four [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average exercise price, options outstanding		3.80
Weighted average grant-date stock price, options outstanding		3.80
Weighted average exercise price, options exercisable	3.80	4.70
Weighted average grant-date stock price, options exercisable	$ 3.80	$ 4.70
Stock Options Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding	287,500	199,167
Number of options exercisable	45,833	60,000
Weighted average exercise price, options exercisable		$ 5.10
Weighted average grant-date stock price, options exercisable		5.10
Stock Options Five [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average exercise price, options outstanding	$ 2	4
Weighted average grant-date stock price, options outstanding	2	4
Weighted average exercise price, options exercisable	4
Weighted average grant-date stock price, options exercisable	4
Stock Options Five [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average exercise price, options outstanding	2.70	4.70
Weighted average grant-date stock price, options outstanding	2.70	$ 4.70
Weighted average exercise price, options exercisable	4.70
Weighted average grant-date stock price, options exercisable	$ 4.70
Stock Options Six [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding	130,000	60,000
Weighted average exercise price, options outstanding		$ 5.10
Weighted average grant-date stock price, options outstanding		$ 5.10
Number of options exercisable	60,000
Weighted average exercise price, options exercisable	$ 5.10
Weighted average grant-date stock price, options exercisable	5.10
Stock Options Six [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average exercise price, options outstanding	3.10
Weighted average grant-date stock price, options outstanding	3.10
Stock Options Six [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average exercise price, options outstanding	3.80
Weighted average grant-date stock price, options outstanding	$ 3.80
Stock Options Seven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding	49,167
Stock Options Seven [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average exercise price, options outstanding	$ 4
Weighted average grant-date stock price, options outstanding	4
Stock Options Seven [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average exercise price, options outstanding	4.70
Weighted average grant-date stock price, options outstanding	$ 4.70
Stock Options Eight [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding	60,000
Weighted average exercise price, options outstanding	$ 5.10
Weighted average grant-date stock price, options outstanding	$ 5.10

Warrants (Details Narrative)

Warrants (Details Narrative) - USD ($)

Sep. 10, 2014

Sep. 09, 2014

Aug. 25, 2014

May 31, 2015

Sep. 30, 2016

Sep. 30, 2015

Mar. 31, 2016

Mar. 31, 2015

May 11, 2015

Sep. 24, 2014

Sep. 08, 2014

Mar. 31, 2014

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Warrants outstanding

7,632,128

2,002,718

1,212,718

772,717

Exercise price of warrants

$ 0.65

$ 3.50

$ 3.90

$ 4.10

Proceeds from warrant

$ 352,000

Cost to induce exercise of warrants

$ 21,218

$ (961,767)

Derivative liability

663,810

401,127

$ 1,406,596

$ 1,694,651

$ 961,767

Stock-based compensation expense

129,749

$ 93,468

Aggregate intrinsic value of all outstanding and exercisable warrants

$ 5,350,263

$ 0

Warrants issued

7,950,000

1,290,000

807,648

Fair value of warrants vesting

$ 614,846

Common stock issuable

99,970

Employment Contracts [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of shares called by exercise of warrants

440,000

Exercise price of warrants

$ 3

Warrant expiration period

10 years

Stock-based compensation expense

182,072

$ 432,772

Unamortized cost of outstanding warrants

$ 91,036

Employment Contracts [Member] | Share Based Compensation Award Tranche One [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of shares called by exercise of warrants

80,000

Stock-based compensation expense

201,680

Employment Contracts [Member] | Share Based Compensation Award Tranche Two [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of shares called by exercise of warrants

200,000

Fair value of warrants vesting

$ 504,204

Employment Contracts [Member] | Share Based Compensation Award Tranche Two [Member] | Minimum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Warrant expiration period

1 year

Employment Contracts [Member] | Share Based Compensation Award Tranche Two [Member] | Maximum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Warrant expiration period

3 years

Employment Contracts [Member] | Share Based Compensation Award Tranche Three [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of shares called by exercise of warrants

160,000

Series A Warrants [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of shares called by exercise of warrants

500,000

Exercise price of warrants

$ 4.50

Warrant expiration period

5 years

Series B Warrants [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of shares called by exercise of warrants

500,000

Exercise price of warrants

$ 3.50

Warrant expiration period

9 months

Series C Warrants [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of shares called by exercise of warrants

250,000

Exercise price of warrants

$ 4

Warrant expiration period

1 year

Placement Agent Warrants [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of shares called by exercise of warrants

40,000

Exercise price of warrants

$ 3.75

Warrant expiration period

5 years

Minumum exercise price for automatic reset provision

$ 2

Warrant [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Derivative liability

$ 401,127

Early Exercise Warrants [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of shares called by exercise of warrants

367,647

Warrants outstanding

367,647

Exercise price of warrants

$ 4

$ 4.20

Proceeds from warrant

$ 1,470,589

Cost to induce exercise of warrants

$ 21,218

Replacement Warrants [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of shares called by exercise of warrants

367,647

Exercise price of warrants

$ 4.50

Cost to induce exercise of warrants

$ 940,549

Warrant expiration period

5 years

Minumum exercise price for automatic reset provision

$ 2

Warrants (Details Narrative) (1

Warrants (Details Narrative) (10Q) - USD ($)	Aug. 25, 2014	May 31, 2016	Sep. 30, 2016	Sep. 30, 2015	Mar. 31, 2016	Mar. 31, 2015	May 31, 2015	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price of warrants			$ 0.65		$ 3.50	$ 3.90		$ 4.10
Stock-based compensation expense			$ 129,749	$ 93,468
Fair value of warrants vesting					$ 614,846
Fair value of accumulated amortization warrants, vested			129,749	$ 59,234	161,936	$ 329,511
Proceeds from warrant holders			$ 352,000
Common stock issued upon exercise of warrants, shares			2,070,590
Aggregate intrinsic value of all outstanding and exercisable warrants			$ 5,350,263		0
Employment Contracts [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares called by exercise of warrants	440,000
Exercise price of warrants	$ 3
Warrant expiration period	10 years
Stock-based compensation expense					$ 182,072	432,772
Number of warrant shares up on achievement			160,000
Employment Contracts [Member] | Share Based Compensation Award Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares called by exercise of warrants	80,000
Stock-based compensation expense						$ 201,680
Employment Contracts [Member] | Share Based Compensation Award Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares called by exercise of warrants	200,000
Fair value of warrants vesting	$ 504,204
Employment Contracts [Member] | Share Based Compensation Award Tranche Two [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrant expiration period	1 year
Employment Contracts [Member] | Share Based Compensation Award Tranche Two [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrant expiration period	3 years
Securities Purchase Agreement Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares called by exercise of warrants		7,950,000					1,250,001
Exercise price of warrants		$ 0.17
Warrant expiration date		Feb. 4, 2017
Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of accumulated amortization warrants, vested			$ 649,860
Amortization of vested warrants			$ 35,014

Warrants - Summary of Warrants

Warrants - Summary of Warrants to Purchase Common Stock Issued (Details) - $ / shares	6 Months Ended	12 Months Ended
	Sep. 30, 2016	Mar. 31, 2016	Mar. 31, 2015
Warrants and Rights Note Disclosure [Abstract]
Shares, Beginning balance	2,002,718	1,212,718	772,717
Shares, Granted	7,950,000	1,290,000	807,648
Shares, Exercised	(2,070,590)		(367,647)
Shares, Expired	(250,000)
Shares, Cancelled		(500,000)
Shares, Balance	7,632,128	2,002,718	1,212,718
Shares, exercisable	7,632,128	2,002,718
Weighted Average Exercise Price, Beginning balance	$ 3.50	$ 3.90	$ 4.10
Weighted Average Exercise Price, Granted	0.17	3.40	3.70
Weighted Average Exercise Price, Exercised	0.17		4
Weighted Average Exercise Price, Expired	4
Weighted Average Exercise Price, Cancelled		3.50
Weighted Average Exercise Price, Balance	0.65	3.50	$ 3.90
Weighted Average Exercise Price, Exercisable Balance	$ 0.65	$ 3.50

Income Taxes (Details Narrative

Income Taxes (Details Narrative)	12 Months Ended
	Mar. 31, 2016USD ($)
Income Tax Disclosure [Abstract]
Net operating loss carry forwards	$ 8,900,000
Future income tax description	through 2,030
Liability for unrecognized tax benefits	$ 0

Distribution and License Agre48

Distribution and License Agreements (Details Narrative) - shares	Aug. 25, 2014	Aug. 31, 2014	Sep. 30, 2016	Mar. 31, 2016
Number of warrants or shares vested			2,500
Vesting period of shares granted			1 year 4 months 24 days
Maximum [Member] | Qualipride International [Member]
Handling charge, percent of product cost				2.00%
Sales commission charge as percent of product cost				5.00%
Employment Contracts [Member]
Number of shares called by exercise of warrants	440,000
Employment Contracts [Member] | Share Based Compensation Award Tranche One [Member]
Number of shares called by exercise of warrants	80,000
Employment Contracts [Member] | Share Based Compensation Award Tranche Two [Member]
Number of shares called by exercise of warrants	200,000
Employment Contracts [Member] | Share Based Compensation Award Tranche Three [Member]
Number of shares called by exercise of warrants	160,000
Number of warrants or shares vested	100,000
Employment Contracts [Member] | Qualipride International [Member]
Stock-based compensation, shares issued during period	240,000
Number of shares called by exercise of warrants	440,000
Employment Contracts [Member] | Qualipride International [Member] | Share Based Compensation Award Tranche One [Member]
Number of shares called by exercise of warrants	80,000
Number of warrants or shares vested	40,000
Employment Contracts [Member] | Qualipride International [Member] | Share Based Compensation Award Tranche Two [Member]
Number of shares called by exercise of warrants	200,000
Number of warrants or shares vested	100,000
Employment Contracts [Member] | Qualipride International [Member] | Share Based Compensation Award Tranche Three [Member]
Number of shares called by exercise of warrants	160,000
Number of warrants or shares vested	100,000
Employment Contracts [Member] | Maximum [Member] | Qualipride International [Member] | Share Based Compensation Award Tranche Two [Member]
Vesting period of shares granted		3 years
Employment Contracts [Member] | Minimum [Member] | Qualipride International [Member] | Share Based Compensation Award Tranche Two [Member]
Vesting period of shares granted		1 year

Distribution and License Agre49

Distribution and License Agreements (Details Narrative) (10Q) - USD ($)	Aug. 31, 2014	Sep. 30, 2016	Sep. 30, 2015	Mar. 31, 2016	Mar. 31, 2015	Oct. 11, 2011	Oct. 09, 2011
Common stock shares issued		14,380,968		7,911,708	7,296,892	51,450,000	7,350,000
Fair value of common stock amortized		$ 129,749	$ 59,234	$ 161,936	$ 329,511
Vesting period of shares granted		1 year 4 months 24 days
fair value of warrant		$ 35,014	$ 112,045	$ 182,072	$ 432,772
Warrant [Member]
Fair value of common stock amortized		649,860
License Agreements [Member]
Common stock shares issued	1,400,000
Fair value of common stock amortized	$ 420,000
Vesting period of shares granted	3 years
Accumulated amortization of shares		$ 395,000
Number of warrant to purchase shares		440,000
fair value of warrant		$ 705,880

Related Party Transactions an50

Related Party Transactions and Lease Obligations (Details Narrative) - USD ($)	1 Months Ended	6 Months Ended		12 Months Ended
	Apr. 23, 2012	Sep. 30, 2016	Sep. 30, 2015	Mar. 31, 2016	Mar. 31, 2015	Aug. 22, 2012
Operating Leased Assets [Line Items]
Operating leases, net rent expense		$ 0	$ 15,800	$ 30,600	$ 49,000
Carlson Lease [Member]
Operating Leased Assets [Line Items]
Payments for rent per month	$ 2,300			2,300
Security deposit	$ 1,500
Sacramento Lease [Member]
Operating Leased Assets [Line Items]
Payments for rent per month				$ 1,000
Security deposit						$ 1,000

Related Party Transactions an51

Related Party Transactions and Lease Obligations (Details Narrative) (10Q) - USD ($)	1 Months Ended	6 Months Ended		12 Months Ended
	Apr. 23, 2012	Sep. 30, 2016	Sep. 30, 2015	Mar. 31, 2016	Mar. 31, 2015
Operating Leased Assets [Line Items]
Operating leases, net rent expense		$ 0	$ 15,800	$ 30,600	$ 49,000
Carlson Lease [Member]
Operating Leased Assets [Line Items]
Payments for rent per month	$ 2,300			$ 2,300
Security deposit	$ 1,500
Lease expiration date	May 1, 2017

Commitments (Details Narrative)

Commitments (Details Narrative) - Licensing Agreements [Member]	12 Months Ended
	Mar. 31, 2016USD ($)
Maximum proceeds from patent prosecution cost	$ 50,000
Royalties owed as percent of sale price of products developed using licensed intellectual property	0.50%
Minimum annual royalty pursuant to license agreement, year three and beyond	$ 10,000

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)

Aug. 16, 2016

Oct. 31, 2016

Sep. 30, 2016

Jul. 31, 2016

May 31, 2016

Sep. 30, 2016

Sep. 30, 2016

Mar. 31, 2016

Mar. 31, 2015

Mar. 31, 2014

Oct. 11, 2011

Oct. 09, 2011

Subsequent Event [Line Items]

Exercise price of warrants

$ 0.65

$ 0.65

$ 0.65

$ 3.50

$ 3.90

$ 4.10

Proceeds from issuance of warrants

$ 352,000

Common stock, shares authorized

1,000,000,000

1,000,000,000

1,000,000,000

1,000,000,000

1,000,000,000

525,000,000

75,000,000

Vesting period of options or warrants granted

1 year 4 months 24 days

Weighted Average Exercise Price, Granted

$ 0.51

Issuance of stock and warrants, value

$ 99,970

$ 165,030

$ (403,077)

Employees [Member]

Subsequent Event [Line Items]

Options granted during period (shares)

137,500

112,500

Grant-date fair value of options granted

$ 233,000

$ 300,000

Expected volatility rate of options granted

76.26%

81.84%

Expected discount rate of options granted

2.19%

1.62%

Expected dividend yield of options granted

0.00%

0.00%

Expected life of options granted

5 years

5 years

Expiration period of options granted

10 years

10 years

Consultants [Member]

Subsequent Event [Line Items]

Options granted during period (shares)

140,000

22,500

Grant-date fair value of options granted

$ 131,000

$ 88,000

Expected volatility rate of options granted

76.26%

Expected discount rate of options granted

2.17%

2.17%

Expected dividend yield of options granted

0.00%

0.00%

Expected life of options granted

5 years

5 years

Minimum [Member]

Subsequent Event [Line Items]

Common stock, shares authorized

525,000,000

525,000,000

525,000,000

525,000,000

Minimum [Member] | Employees [Member]

Subsequent Event [Line Items]

Vesting period of options or warrants granted

0 months

0 months

Minimum [Member] | Consultants [Member]

Subsequent Event [Line Items]

Vesting period of options or warrants granted

0 months

0 months

Expiration period of options granted

3 years

5 years

Maximum [Member]

Subsequent Event [Line Items]

Common stock, shares authorized

1,000,000,000

1,000,000,000

1,000,000,000

1,000,000,000

Maximum [Member] | Employees [Member]

Subsequent Event [Line Items]

Vesting period of options or warrants granted

36 months

36 months

Maximum [Member] | Consultants [Member]

Subsequent Event [Line Items]

Vesting period of options or warrants granted

36 months

36 months

Expiration period of options granted

10 years

10 years

Subsequent Event [Member]

Subsequent Event [Line Items]

Issuance of stock and warrants, shares

2,650,000

Number of shares called by exercise of warrants

2,070,590

7,950,000

2,070,590

2,070,590

Shares issued, price per share

$ 0.10

Exercise price of warrants

$ 0.17

Exercise term of warrants issued

6 months

Proceeds from issuance of warrants

$ 7,950,000

$ 204,000

$ 352,000

$ 265,000

Subsequent Event [Member] | Employees [Member]

Subsequent Event [Line Items]

Options granted during period (shares)

1,525,703

Grant-date fair value of options granted

$ 365,330

Vesting period of options or warrants granted

24 months

Expected volatility rate of options granted

126.34%

Expected discount rate of options granted

1.60%

Expected dividend yield of options granted

0.00%

Expected life of options granted

5 years

Weighted Average Exercise Price, Granted

$ 0.50

Expiration period of options granted

10 years

Subsequent Event [Member] | Consultants [Member]

Subsequent Event [Line Items]

Options granted during period (shares)

185,118

312,500

Grant-date fair value of options granted

$ 44,326

$ 220,000

Vesting period of options or warrants granted

24 months

Expected volatility rate of options granted

126.34%

Expected discount rate of options granted

1.60%

Expected dividend yield of options granted

0.00%

Expected life of options granted

5 years

Weighted Average Exercise Price, Granted

$ 0.50

Expiration period of options granted

10 years

Subsequent Event [Member] | Consultant One [Member]

Subsequent Event [Line Items]

Options granted during period (shares)

50,000

Grant-date fair value of options granted

$ 40,725

Vesting period of options or warrants granted

24 months

Expected volatility rate of options granted

126.34%

Expected discount rate of options granted

1.60%

Expected dividend yield of options granted

0.00%

Expected life of options granted

5 years

Weighted Average Exercise Price, Granted

$ 0.96

Expiration period of options granted

10 years

Subsequent Event [Member] | Chief Executive Officer and Chairman of Board of Directors [Member] | Restricted Common Stock [Member]

Subsequent Event [Line Items]

Issuance of stock and warrants, shares

1,436,170

Vesting period of options or warrants granted

20 months

Issuance of stock and warrants, value

$ 718,015

Subsequent Event [Member] | Minimum [Member]

Subsequent Event [Line Items]

Common stock, shares authorized

525,000,000

Subsequent Event [Member] | Maximum [Member]

Subsequent Event [Line Items]

Common stock, shares authorized

1,000,000,000

Subsequent Event (Details Narra

Subsequent Event (Details Narrative) (10Q) - USD ($)	Aug. 16, 2016	Oct. 31, 2016	Sep. 30, 2016	May 31, 2016	Sep. 30, 2016
Proceeds from issuance of warrants					$ 352,000
Subsequent Event [Member]
Proceeds from issuance of warrants	$ 7,950,000	$ 204,000	$ 352,000	$ 265,000
Warrants issued to purchase number of common stock		1,200,000